Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2597363,Concentration,Concentration of plasma AVP increased slightly from 3.8 +/- 1.5 pg/ml after induction and increased 3-fold after sternotomy.,Responses of vasopressin release in patients with cardiopulmonary bypass anesthetized with enflurane and morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2597363/),[pg] / [ml],3.8,344,DB00599,Thiopental
,9357892,steady state volume of distribution,"The human pharmacokinetic model is characterized by a steady state volume of distribution of 2.2 l/kg, an elimination clearance of 0.22 l/min, and a terminal half-life of 9 h.",Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357892/),[l] / [kg],2.2,2978,DB00599,Thiopental
,9357892,elimination clearance,"The human pharmacokinetic model is characterized by a steady state volume of distribution of 2.2 l/kg, an elimination clearance of 0.22 l/min, and a terminal half-life of 9 h.",Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357892/),[l] / [min],0.22,2979,DB00599,Thiopental
,9357892,terminal half-life,"The human pharmacokinetic model is characterized by a steady state volume of distribution of 2.2 l/kg, an elimination clearance of 0.22 l/min, and a terminal half-life of 9 h.",Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357892/),h,9,2980,DB00599,Thiopental
,9357892,peak arterial concentrations,"Greater peak arterial concentrations are predicted in subjects with a low versus a high cardiac output (3.1 and 9.4 l/min), and in subjects who are lean versus obese (56 and 135 kg).",Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357892/),[l] / [min],3.1,2981,DB00599,Thiopental
,9357892,peak arterial concentrations,"Greater peak arterial concentrations are predicted in subjects with a low versus a high cardiac output (3.1 and 9.4 l/min), and in subjects who are lean versus obese (56 and 135 kg).",Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357892/),[l] / [min],9.4,2982,DB00599,Thiopental
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8706,DB00599,Thiopental
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],19.4,8707,DB00599,Thiopental
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],688,8708,DB00599,Thiopental
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],591,8709,DB00599,Thiopental
,8678276,peak serum IFCs,In our study 1.69 MAC-h sevoflurane produced peak serum IFCs of 34.5 mumol/l.,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8710,DB00599,Thiopental
,6869869,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state was of 2.3 +/- 0.5 1 X kg-1 in the controls and of 3.5 +/- 1.9 1 X kg-1 in the patients with cirrhosis.,Thiopental pharmacokinetics in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),[1] / [kg],2.3,17478,DB00599,Thiopental
,6869869,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state was of 2.3 +/- 0.5 1 X kg-1 in the controls and of 3.5 +/- 1.9 1 X kg-1 in the patients with cirrhosis.,Thiopental pharmacokinetics in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),[1] / [kg],3.5,17479,DB00599,Thiopental
,6869869,plasma clearance,Thiopental plasma clearance based upon total drug concentrations was 3.9 +/- 1.2 ml X min-1 X kg-1 in the normal group and did not differ significantly in the patients with cirrhosis: 4.4 +/- 2.2 ml X min-1 X kg-1.,Thiopental pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),[ml] / [kg·min],3.9,17480,DB00599,Thiopental
,6869869,plasma clearance,Thiopental plasma clearance based upon total drug concentrations was 3.9 +/- 1.2 ml X min-1 X kg-1 in the normal group and did not differ significantly in the patients with cirrhosis: 4.4 +/- 2.2 ml X min-1 X kg-1.,Thiopental pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),[ml] / [kg·min],4.4,17481,DB00599,Thiopental
,6869869,elimination half-life,The elimination half-life was of 529 +/- 97 min in the controls and of 714 +/- 252 min in the patients with cirrhosis.,Thiopental pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),min,529,17482,DB00599,Thiopental
,6869869,elimination half-life,The elimination half-life was of 529 +/- 97 min in the controls and of 714 +/- 252 min in the patients with cirrhosis.,Thiopental pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),min,714,17483,DB00599,Thiopental
,6869869,free fraction,The thiopental free fraction was 14.5 +/- 3.4% in the controls and was increased significantly to 25.2 +/- 3.9% in the patients with cirrhosis.,Thiopental pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),%,14.5,17484,DB00599,Thiopental
,6869869,free fraction,The thiopental free fraction was 14.5 +/- 3.4% in the controls and was increased significantly to 25.2 +/- 3.9% in the patients with cirrhosis.,Thiopental pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),%,25.2,17485,DB00599,Thiopental
,6869869,intrinsic clearance,"Thiopental intrinsic clearance was decreased insignificantly (P = 0.06) from 28.3 +/- 9.0 ml X min-1 X kg-1 in the controls to 18.2 +/- 10.5 ml X min-1 X kg-1 in those with cirrhosis, suggesting that these patients may have a decreased capacity for thiopental metabolism.",Thiopental pharmacokinetics in patients with cirrhosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),[ml] / [kg·min],28.3,17486,DB00599,Thiopental
,6869869,intrinsic clearance,"Thiopental intrinsic clearance was decreased insignificantly (P = 0.06) from 28.3 +/- 9.0 ml X min-1 X kg-1 in the controls to 18.2 +/- 10.5 ml X min-1 X kg-1 in those with cirrhosis, suggesting that these patients may have a decreased capacity for thiopental metabolism.",Thiopental pharmacokinetics in patients with cirrhosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869869/),[ml] / [kg·min],18.2,17487,DB00599,Thiopental
,4007037,half-life,The mean half-life of thiopentone in the newborns was about double that in their mothers (15 vs 7 h) confirming a disposition similar to other barbiturates.,Elimination kinetics of thiopentone in mothers and their newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007037/),h,15,18747,DB00599,Thiopental
,4007037,half-life,The mean half-life of thiopentone in the newborns was about double that in their mothers (15 vs 7 h) confirming a disposition similar to other barbiturates.,Elimination kinetics of thiopentone in mothers and their newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007037/),h,7,18748,DB00599,Thiopental
,4007037,renal clearance,For the first time renal clearance of thiopentone was estimated in the newborn; 0.074 ml/h/kg.,Elimination kinetics of thiopentone in mothers and their newborn infants. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007037/),[ml] / [h·kg],0.074,18749,DB00599,Thiopental
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,176,19818,DB00599,Thiopental
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,516,19819,DB00599,Thiopental
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,27.1,19820,DB00599,Thiopental
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,42.5,19821,DB00599,Thiopental
,2394062,total duration of neuromuscular blockade,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,51.8,19822,DB00599,Thiopental
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,9.6,19823,DB00599,Thiopental
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,64.1,19824,DB00599,Thiopental
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,16.7,19825,DB00599,Thiopental
,8564666,E,"The ED50 value of thiopentone decreased up to 15 minutes after DBP (about 1.1 mg.kg-1 in both age groups) and increased after 30, 45 and 60 minutes, the increase being higher in the patients aged 40 to 50.",[Influence of droperidol on the hypnotic effect of thiopental]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8564666/),,1,24823,DB00599,Thiopental
,8048569,Late proximal (TF/P)Li,"Late proximal (TF/P)Li was 1.01 after oral Li+, 1.16 after intravenous Li+ (P < 0.01), and 1.00 during osmotic diuresis.",Active lithium transport by rat renal proximal tubule: a micropuncture study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8048569/),,1.01,26632,DB00599,Thiopental
,8048569,Late proximal (TF/P)Li,"Late proximal (TF/P)Li was 1.01 after oral Li+, 1.16 after intravenous Li+ (P < 0.01), and 1.00 during osmotic diuresis.",Active lithium transport by rat renal proximal tubule: a micropuncture study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8048569/),,1.16,26633,DB00599,Thiopental
,8048569,Late proximal (TF/P)Li,"Late proximal (TF/P)Li was 1.01 after oral Li+, 1.16 after intravenous Li+ (P < 0.01), and 1.00 during osmotic diuresis.",Active lithium transport by rat renal proximal tubule: a micropuncture study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8048569/),,1.00,26634,DB00599,Thiopental
,6507924,free fractions,"The degree of serum protein binding of thiopental also was similar in pediatric and adult patients with free fractions of 13.2% +/- 1.5% and 13.6% +/- 1.3%, respectively.",The pharmacokinetics of thiopental in pediatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507924/),%,13.2,28534,DB00599,Thiopental
,6507924,free fractions,"The degree of serum protein binding of thiopental also was similar in pediatric and adult patients with free fractions of 13.2% +/- 1.5% and 13.6% +/- 1.3%, respectively.",The pharmacokinetics of thiopental in pediatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507924/),%,13.6,28535,DB00599,Thiopental
,6507924,Total drug clearance,Total drug clearance was 6.6 +/- 2.2 ml . kg-1 . min-1 for pediatric patients and 3.1 +/- 0.5 ml . kg-1 . min-1 for adults (P less than 0.001).,The pharmacokinetics of thiopental in pediatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507924/),[ml] / [kg·min],6.6,28536,DB00599,Thiopental
,6507924,Total drug clearance,Total drug clearance was 6.6 +/- 2.2 ml . kg-1 . min-1 for pediatric patients and 3.1 +/- 0.5 ml . kg-1 . min-1 for adults (P less than 0.001).,The pharmacokinetics of thiopental in pediatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507924/),[ml] / [kg·min],3.1,28537,DB00599,Thiopental
,6507924,elimination half-time,"The elimination half-time of 6.1 +/- 3.3 hours found in pediatric patients was significantly shorter (P less than 0.005) than that for adults, 12 +/- 6 hours.",The pharmacokinetics of thiopental in pediatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507924/),h,6.1,28538,DB00599,Thiopental
,6507924,elimination half-time,"The elimination half-time of 6.1 +/- 3.3 hours found in pediatric patients was significantly shorter (P less than 0.005) than that for adults, 12 +/- 6 hours.",The pharmacokinetics of thiopental in pediatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507924/),h,12,28539,DB00599,Thiopental
,3176834,elimination half-life,"The elimination half-life of midazolam after i.m. administration (Group 2) was 6.6 +/- 1.2 h (mean +/- s.e. mean), which was significantly longer (P less than 0.05) than the 3.9 +/- 0.3 h observed after the combined i.m. and i.v. administration of midazolam (Group 1), and significantly longer than 2.9 h obtained from a calculated i.v. administration curve.",Prolonged elimination of midazolam after i.m. administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176834/),h,6.6,34699,DB00599,Thiopental
,3176834,elimination half-life,"The elimination half-life of midazolam after i.m. administration (Group 2) was 6.6 +/- 1.2 h (mean +/- s.e. mean), which was significantly longer (P less than 0.05) than the 3.9 +/- 0.3 h observed after the combined i.m. and i.v. administration of midazolam (Group 1), and significantly longer than 2.9 h obtained from a calculated i.v. administration curve.",Prolonged elimination of midazolam after i.m. administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176834/),h,3.9,34700,DB00599,Thiopental
,3176834,elimination half-life,"The elimination half-life of midazolam after i.m. administration (Group 2) was 6.6 +/- 1.2 h (mean +/- s.e. mean), which was significantly longer (P less than 0.05) than the 3.9 +/- 0.3 h observed after the combined i.m. and i.v. administration of midazolam (Group 1), and significantly longer than 2.9 h obtained from a calculated i.v. administration curve.",Prolonged elimination of midazolam after i.m. administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176834/),h,2.9,34701,DB00599,Thiopental
,3826788,apparent volume of distribution (Vd,"In pregnant women, the apparent volume of distribution (Vd = 10.02 +/- 3.26 l X kg-1), plasma clearance (Cl = 22.03 +/- 7.55 l X h-1) and elimination half-life (t 1/2 (3) = 21.71 +/- 11.12 h) were significantly greater than in the surgical patients (Vd = 4.22 +/- 1.16 l X kg-1; Cl = 12.49 +/- 3.50 l X h-1; t 1/2 (3) = 13.79 +/- 3.09 h).",[Pharmacokinetics of thiopental in women and newborn infants]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826788/),[l] / [kg],10.02,36519,DB00599,Thiopental
,3826788,plasma clearance (Cl,"In pregnant women, the apparent volume of distribution (Vd = 10.02 +/- 3.26 l X kg-1), plasma clearance (Cl = 22.03 +/- 7.55 l X h-1) and elimination half-life (t 1/2 (3) = 21.71 +/- 11.12 h) were significantly greater than in the surgical patients (Vd = 4.22 +/- 1.16 l X kg-1; Cl = 12.49 +/- 3.50 l X h-1; t 1/2 (3) = 13.79 +/- 3.09 h).",[Pharmacokinetics of thiopental in women and newborn infants]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826788/),[l] / [h],22.03,36520,DB00599,Thiopental
,3826788,elimination half-life (t 1/2 (3),"In pregnant women, the apparent volume of distribution (Vd = 10.02 +/- 3.26 l X kg-1), plasma clearance (Cl = 22.03 +/- 7.55 l X h-1) and elimination half-life (t 1/2 (3) = 21.71 +/- 11.12 h) were significantly greater than in the surgical patients (Vd = 4.22 +/- 1.16 l X kg-1; Cl = 12.49 +/- 3.50 l X h-1; t 1/2 (3) = 13.79 +/- 3.09 h).",[Pharmacokinetics of thiopental in women and newborn infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826788/),h,21.71,36521,DB00599,Thiopental
,3826788,Vd,"In pregnant women, the apparent volume of distribution (Vd = 10.02 +/- 3.26 l X kg-1), plasma clearance (Cl = 22.03 +/- 7.55 l X h-1) and elimination half-life (t 1/2 (3) = 21.71 +/- 11.12 h) were significantly greater than in the surgical patients (Vd = 4.22 +/- 1.16 l X kg-1; Cl = 12.49 +/- 3.50 l X h-1; t 1/2 (3) = 13.79 +/- 3.09 h).",[Pharmacokinetics of thiopental in women and newborn infants]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826788/),[l] / [kg],4.22,36522,DB00599,Thiopental
,3826788,Cl,"In pregnant women, the apparent volume of distribution (Vd = 10.02 +/- 3.26 l X kg-1), plasma clearance (Cl = 22.03 +/- 7.55 l X h-1) and elimination half-life (t 1/2 (3) = 21.71 +/- 11.12 h) were significantly greater than in the surgical patients (Vd = 4.22 +/- 1.16 l X kg-1; Cl = 12.49 +/- 3.50 l X h-1; t 1/2 (3) = 13.79 +/- 3.09 h).",[Pharmacokinetics of thiopental in women and newborn infants]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826788/),[l] / [h],12.49,36523,DB00599,Thiopental
,3826788,t 1/2 (3),"In pregnant women, the apparent volume of distribution (Vd = 10.02 +/- 3.26 l X kg-1), plasma clearance (Cl = 22.03 +/- 7.55 l X h-1) and elimination half-life (t 1/2 (3) = 21.71 +/- 11.12 h) were significantly greater than in the surgical patients (Vd = 4.22 +/- 1.16 l X kg-1; Cl = 12.49 +/- 3.50 l X h-1; t 1/2 (3) = 13.79 +/- 3.09 h).",[Pharmacokinetics of thiopental in women and newborn infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826788/),h,13.79,36524,DB00599,Thiopental
,3826788,t 1/2(e),Elimination half-life in neonates (t 1/2(e) = 17.9 +/- 9.7 h) was not different from half-life in mothers or in the surgical group.,[Pharmacokinetics of thiopental in women and newborn infants]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826788/),h,17.9,36525,DB00599,Thiopental
,3826788,concentrations,"At delivery, the simultaneous concentrations were 5.3 +/- 1.3 mg X l-1 in venous blood and 3.8 +/- 1.6 mg X l-1 in cord venous blood.",[Pharmacokinetics of thiopental in women and newborn infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826788/),[mg] / [l],5.3,36526,DB00599,Thiopental
,3826788,concentrations,"At delivery, the simultaneous concentrations were 5.3 +/- 1.3 mg X l-1 in venous blood and 3.8 +/- 1.6 mg X l-1 in cord venous blood.",[Pharmacokinetics of thiopental in women and newborn infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826788/),[mg] / [l],3.8,36527,DB00599,Thiopental
,3081598,serum clearance,"The mean +/- SD alfentanil serum clearance, volume of distribution at steady state (Vss), and elimination half-life were 5.2 +/- 2.0 mL/min/kg, 0.47 +/- 0.1 L/kg, and 97 +/- 52 minutes, respectively.",The pharmacokinetics of alfentanil in gynecologic surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),[ml] / [kg·min],5.2,37375,DB00599,Thiopental
,3081598,volume of distribution at steady state (Vss),"The mean +/- SD alfentanil serum clearance, volume of distribution at steady state (Vss), and elimination half-life were 5.2 +/- 2.0 mL/min/kg, 0.47 +/- 0.1 L/kg, and 97 +/- 52 minutes, respectively.",The pharmacokinetics of alfentanil in gynecologic surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),[l] / [kg],0.47,37376,DB00599,Thiopental
,3081598,elimination half-life,"The mean +/- SD alfentanil serum clearance, volume of distribution at steady state (Vss), and elimination half-life were 5.2 +/- 2.0 mL/min/kg, 0.47 +/- 0.1 L/kg, and 97 +/- 52 minutes, respectively.",The pharmacokinetics of alfentanil in gynecologic surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),min,97,37377,DB00599,Thiopental
,3081598,fraction of alfentanil unbound in serum (fu),The mean fraction of alfentanil unbound in serum (fu) was 0.18 +/- 0.08.,The pharmacokinetics of alfentanil in gynecologic surgical patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),,0.18,37378,DB00599,Thiopental
,6824168,fraction of thiopental loss from the central compartment,The fraction of thiopental loss from the central compartment due to metabolism was calculated to be 0.14 +/- 0.06 (mean +/- SD) at 1 min and 0.18 +/) 0.04 at 15 min.,The role of metabolism and protein binding in thiopental anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824168/),,0.14,39440,DB00599,Thiopental
,6824168,fraction of thiopental loss from the central compartment,The fraction of thiopental loss from the central compartment due to metabolism was calculated to be 0.14 +/- 0.06 (mean +/- SD) at 1 min and 0.18 +/) 0.04 at 15 min.,The role of metabolism and protein binding in thiopental anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824168/),,0.18,39441,DB00599,Thiopental
,6824168,protein binding,The protein binding of thiopental from 0.5 to 15 min was found to be linear over a concentration range of 93 +/- 60 micrograms/ml to 6.9 +/- 0.62 micrograms/ml.,The role of metabolism and protein binding in thiopental anesthesia. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824168/),min,0.5 to 15,39442,DB00599,Thiopental
,10470766,infusion rate,"The median duration of infusion of methohexitone was 137 hrs (minimum, 27 hrs; maximum, 445 hrs), with a median infusion rate of 62.5 microg/kg/min (minimum, 22.5 microg/kg/min; maximum, 116.2 microg/kg/min).","Elimination of methohexitone after long-term, high-dose infusion in patients with critically elevated intracranial pressure. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470766/),[μg] / [kg·min],62.5,40489,DB00599,Thiopental
,10470766,infusion rate,"The median duration of infusion of methohexitone was 137 hrs (minimum, 27 hrs; maximum, 445 hrs), with a median infusion rate of 62.5 microg/kg/min (minimum, 22.5 microg/kg/min; maximum, 116.2 microg/kg/min).","Elimination of methohexitone after long-term, high-dose infusion in patients with critically elevated intracranial pressure. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470766/),[μg] / [kg·min],22.5,40490,DB00599,Thiopental
,10470766,infusion rate,"The median duration of infusion of methohexitone was 137 hrs (minimum, 27 hrs; maximum, 445 hrs), with a median infusion rate of 62.5 microg/kg/min (minimum, 22.5 microg/kg/min; maximum, 116.2 microg/kg/min).","Elimination of methohexitone after long-term, high-dose infusion in patients with critically elevated intracranial pressure. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470766/),[μg] / [kg·min],116.2,40491,DB00599,Thiopental
,10470766,Plasma concentrations,"Plasma concentrations of methohexitone at burst suppression under concomitant analgesic sedation ranged from 1.6 to 17.3 microg/mL (median, 4.7 microg/mL).","Elimination of methohexitone after long-term, high-dose infusion in patients with critically elevated intracranial pressure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470766/),[μg] / [ml],1.6 to 17.3,40492,DB00599,Thiopental
,10470766,Plasma concentrations,"Plasma concentrations of methohexitone at burst suppression under concomitant analgesic sedation ranged from 1.6 to 17.3 microg/mL (median, 4.7 microg/mL).","Elimination of methohexitone after long-term, high-dose infusion in patients with critically elevated intracranial pressure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470766/),[μg] / [ml],4.7,40493,DB00599,Thiopental
,2503375,clearance,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[ml] / [kg·min],5.2,41034,DB00599,Thiopental
,2503375,volume of distribution,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[1] / [kg],0.63,41035,DB00599,Thiopental
,2503375,elimination half-life,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),min,96.9,41036,DB00599,Thiopental
,8053580,effect-site rate constant,Average population pharmacokinetic parameters from a three-compartment thiopental model were combined with an effect-site rate constant for thiopental equilibration of 0.58 min-1 and a median effect-site concentration of 13.8 mg/l from previously published pharmacokinetic and pharmacodynamic models for thiopental.,Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053580/),1/[min],0.58,43331,DB00599,Thiopental
,8053580,effect-site concentration,Average population pharmacokinetic parameters from a three-compartment thiopental model were combined with an effect-site rate constant for thiopental equilibration of 0.58 min-1 and a median effect-site concentration of 13.8 mg/l from previously published pharmacokinetic and pharmacodynamic models for thiopental.,Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053580/),[mg] / [l],13.8,43332,DB00599,Thiopental
,8053580,effective doses,"Dose requirements increased significantly with increasing infusion rates greater than 150 mg/min; median effective doses for infusion rates of 300, 600, and 1,200 mg/min were significantly different from each other (436, 555, and 711 mg, respectively).",Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053580/),mg,436,43333,DB00599,Thiopental
,8053580,effective doses,"Dose requirements increased significantly with increasing infusion rates greater than 150 mg/min; median effective doses for infusion rates of 300, 600, and 1,200 mg/min were significantly different from each other (436, 555, and 711 mg, respectively).",Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053580/),mg,555,43334,DB00599,Thiopental
,8053580,effective doses,"Dose requirements increased significantly with increasing infusion rates greater than 150 mg/min; median effective doses for infusion rates of 300, 600, and 1,200 mg/min were significantly different from each other (436, 555, and 711 mg, respectively).",Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053580/),mg,711,43335,DB00599,Thiopental
,8053580,effect-site rate constant,This model incorporated a four-compartment thiopental pharmacokinetic model with quantal dose-response data to derive an effect-site rate constant for thiopental equilibration of 0.29 min-1 and a median effect-site concentration for LOC of 11.3 mg/l.,Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053580/),1/[min],0.29,43336,DB00599,Thiopental
,8053580,effect-site concentration,This model incorporated a four-compartment thiopental pharmacokinetic model with quantal dose-response data to derive an effect-site rate constant for thiopental equilibration of 0.29 min-1 and a median effect-site concentration for LOC of 11.3 mg/l.,Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053580/),[mg] / [l],11.3,43337,DB00599,Thiopental
,9422901,volume of the central compartment,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],42.3,44250,DB00599,Thiopental
,9422901,volume of the central compartment,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],55.2,44251,DB00599,Thiopental
,9422901,volume of distribution at steady state,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],168.4,44252,DB00599,Thiopental
,9422901,volume of distribution at steady state,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],225.9,44253,DB00599,Thiopental
,9422901,elimination half-life,The elimination half-life was 50.3 (11.5) min in control patients and significantly greater (68.2 (15.1) min) in the haemodilution patients (P < 0.05).,Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),min,50.3,44254,DB00599,Thiopental
,9422901,elimination half-life,The elimination half-life was 50.3 (11.5) min in control patients and significantly greater (68.2 (15.1) min) in the haemodilution patients (P < 0.05).,Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),min,68.2,44255,DB00599,Thiopental
,2666039,binding,The binding of thiopentone in human serum and in a physiological saline solution (PSS) with 45 g albumin per litre was 85% and remarkably constant over the concentration range between 4 and 80 micrograms/ml.,Individual variation in response to thiopentone. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2666039/),%,85,45001,DB00599,Thiopental
,21342147,Clearance,Clearance at 26 weeks PMA was 0.015 l/min/70 kg and increased to 0.119 l/min/70 kg by 42 weeks PMA.,Thiopentone elimination in newborn infants: exploring Michaelis-Menten kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342147/),[l] / [70·kg·min],0.015,45252,DB00599,Thiopental
,21342147,Clearance,Clearance at 26 weeks PMA was 0.015 l/min/70 kg and increased to 0.119 l/min/70 kg by 42 weeks PMA.,Thiopentone elimination in newborn infants: exploring Michaelis-Menten kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342147/),[l] / [70·kg·min],0.119,45253,DB00599,Thiopental
,21342147,maximum rate of elimination (V(max)),The maximum rate of elimination (V(max)) at 26 weeks PMA was 0.22 mg/min/70 kg and increased to 4.13 mg/min/70 kg by 42 weeks PMA.,Thiopentone elimination in newborn infants: exploring Michaelis-Menten kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342147/),[mg] / [70·kg·min],0.22,45254,DB00599,Thiopental
,21342147,maximum rate of elimination (V(max)),The maximum rate of elimination (V(max)) at 26 weeks PMA was 0.22 mg/min/70 kg and increased to 4.13 mg/min/70 kg by 42 weeks PMA.,Thiopentone elimination in newborn infants: exploring Michaelis-Menten kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342147/),[mg] / [70·kg·min],4.13,45255,DB00599,Thiopental
,21342147,Michaelis constant (K(m)),"The Michaelis constant (K(m)) was 28.3 [between subject variability (BSV) 46.4%, 95% confidence interval (CI) 4.49-99.2] mg/l; intercompartment clearance was 0.44 (BSV 97.5%, 95% CI 0.27-0.63) l/min/70 kg; central volume of distribution was 46.4 (BSV 29.2%, 95% CI 41.7-59.8) l/70 kg; peripheral volume of distribution was 95.7 (BSV 70.3%, 95% CI 61.3-128) l/70 kg.",Thiopentone elimination in newborn infants: exploring Michaelis-Menten kinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342147/),[mg] / [l],28.3,45256,DB00599,Thiopental
,21342147,intercompartment clearance,"The Michaelis constant (K(m)) was 28.3 [between subject variability (BSV) 46.4%, 95% confidence interval (CI) 4.49-99.2] mg/l; intercompartment clearance was 0.44 (BSV 97.5%, 95% CI 0.27-0.63) l/min/70 kg; central volume of distribution was 46.4 (BSV 29.2%, 95% CI 41.7-59.8) l/70 kg; peripheral volume of distribution was 95.7 (BSV 70.3%, 95% CI 61.3-128) l/70 kg.",Thiopentone elimination in newborn infants: exploring Michaelis-Menten kinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342147/),[l] / [70·kg·min],0.44,45257,DB00599,Thiopental
,21342147,central volume of distribution,"The Michaelis constant (K(m)) was 28.3 [between subject variability (BSV) 46.4%, 95% confidence interval (CI) 4.49-99.2] mg/l; intercompartment clearance was 0.44 (BSV 97.5%, 95% CI 0.27-0.63) l/min/70 kg; central volume of distribution was 46.4 (BSV 29.2%, 95% CI 41.7-59.8) l/70 kg; peripheral volume of distribution was 95.7 (BSV 70.3%, 95% CI 61.3-128) l/70 kg.",Thiopentone elimination in newborn infants: exploring Michaelis-Menten kinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342147/),[l] / [70·kg],46.4,45258,DB00599,Thiopental
,21342147,peripheral volume of distribution,"The Michaelis constant (K(m)) was 28.3 [between subject variability (BSV) 46.4%, 95% confidence interval (CI) 4.49-99.2] mg/l; intercompartment clearance was 0.44 (BSV 97.5%, 95% CI 0.27-0.63) l/min/70 kg; central volume of distribution was 46.4 (BSV 29.2%, 95% CI 41.7-59.8) l/70 kg; peripheral volume of distribution was 95.7 (BSV 70.3%, 95% CI 61.3-128) l/70 kg.",Thiopentone elimination in newborn infants: exploring Michaelis-Menten kinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342147/),[l] / [70·kg],95.7,45259,DB00599,Thiopental
,22242687,Areas under the curve,"Areas under the curve for anandamide (mean and 95% CI) were 53.3 (47.4, 59.2) nmol l(-1) 60 min with propofol and 48.5 (43.1, 53.8) nmol l(-1) 60 min with thiopental/sevoflurane (P= NS).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[nM] / [l],53.3,45543,DB00599,Thiopental
,22242687,Areas under the curve,"Areas under the curve for anandamide (mean and 95% CI) were 53.3 (47.4, 59.2) nmol l(-1) 60 min with propofol and 48.5 (43.1, 53.8) nmol l(-1) 60 min with thiopental/sevoflurane (P= NS).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[nM] / [l],48.5,45544,DB00599,Thiopental
,22242687,K(m),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[μM] / [l],16.9,45545,DB00599,Thiopental
,22242687,V(max),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[nM] / [mg·min],44.6,45546,DB00599,Thiopental
,22242687,K(m),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[μM] / [l],16.6,45547,DB00599,Thiopental
,22242687,V(max),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[1·mg·nM] / [min],44.0,45548,DB00599,Thiopental
,10490070,volume of distribution,"For the trans-trans isomer, mean +/- SEM volume of distribution was 0.18+/-0.024 L/kg, median half-life was 34.9 minutes (range, 26.7 to 53.5 minutes), and clearance was 12+/-2 ml/min/kg.",Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490070/),[l] / [kg],0.18,47744,DB00599,Thiopental
,10490070,half-life,"For the trans-trans isomer, mean +/- SEM volume of distribution was 0.18+/-0.024 L/kg, median half-life was 34.9 minutes (range, 26.7 to 53.5 minutes), and clearance was 12+/-2 ml/min/kg.",Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490070/),min,34.9,47745,DB00599,Thiopental
,10490070,clearance,"For the trans-trans isomer, mean +/- SEM volume of distribution was 0.18+/-0.024 L/kg, median half-life was 34.9 minutes (range, 26.7 to 53.5 minutes), and clearance was 12+/-2 ml/min/kg.",Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490070/),[ml] / [kg·min],12,47746,DB00599,Thiopental
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],7.73,48497,DB00599,Thiopental
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],4.54,48498,DB00599,Thiopental
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],3.26,48499,DB00599,Thiopental
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],1.78,48500,DB00599,Thiopental
,3377944,Volume of distribution at steady-state (VDss),Volume of distribution at steady-state (VDss) was smaller in elderly patients (1.36 +/- 0.44 v. 2.27 +/- 0.82 litre kg-1).,Pharmacokinetics of fentanyl in the elderly. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[l] / [kg],1.36,48501,DB00599,Thiopental
,3377944,Volume of distribution at steady-state (VDss),Volume of distribution at steady-state (VDss) was smaller in elderly patients (1.36 +/- 0.44 v. 2.27 +/- 0.82 litre kg-1).,Pharmacokinetics of fentanyl in the elderly. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[l] / [kg],2.27,48502,DB00599,Thiopental
> or =,8602660,train-of-four ratio,All patients were allowed to recover spontaneously to a train-of-four ratio > or = 0.70 after cisatracurium-induced neuromuscular block.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,0.70,54591,DB00599,Thiopental
,8602660,clearances,The clearances (5.28 +/- 1.23 vs.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,5.28,54592,DB00599,Thiopental
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,22.4,54593,DB00599,Thiopental
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,25.5,54594,DB00599,Thiopental
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],38,54595,DB00599,Thiopental
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],103,54596,DB00599,Thiopental
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],101,54597,DB00599,Thiopental
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],253,54598,DB00599,Thiopental
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],902,58068,DB00599,Thiopental
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],914,58069,DB00599,Thiopental
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],4.9,58070,DB00599,Thiopental
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],11.3,58071,DB00599,Thiopental
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,250,58072,DB00599,Thiopental
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,562,58073,DB00599,Thiopental
,11314830,peak arterial concentrations,"Under halothane anaesthesia, the peak arterial concentrations of each drug occurred at the end of the two-minute infusion, and was 42.3 mg/l and 12.3 mg/l for thiopentone and propofol, respectively.",The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[mg] / [l],42.3,66366,DB00599,Thiopental
,11314830,peak arterial concentrations,"Under halothane anaesthesia, the peak arterial concentrations of each drug occurred at the end of the two-minute infusion, and was 42.3 mg/l and 12.3 mg/l for thiopentone and propofol, respectively.",The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[mg] / [l],12.3,66367,DB00599,Thiopental
,11314830,systemic clearance,Propofol had a significantly larger systemic clearance (3.19 l/min) than thiopentone (0.99 l/min).,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[l] / [min],3.19,66368,DB00599,Thiopental
,11314830,systemic clearance,Propofol had a significantly larger systemic clearance (3.19 l/min) than thiopentone (0.99 l/min).,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[l] / [min],0.99,66369,DB00599,Thiopental
,11314830,extraction ratio,The extraction ratio across the brain near the end of the infusions (1.5 min) were 0.85 and 0.46 respectively.,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),,0.85,66370,DB00599,Thiopental
,11314830,extraction ratio,The extraction ratio across the brain near the end of the infusions (1.5 min) were 0.85 and 0.46 respectively.,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),,0.46,66371,DB00599,Thiopental
,8751034,initial volume of distribution (V1),"After a single iv bolus, the mean initial volume of distribution (V1) was 0.481 l.kg-1, and the steady-state volume of distribution (Vss) was 2.16 l.kg-1.",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[l] / [kg],0.481,67864,DB00599,Thiopental
,8751034,steady-state volume of distribution (Vss),"After a single iv bolus, the mean initial volume of distribution (V1) was 0.481 l.kg-1, and the steady-state volume of distribution (Vss) was 2.16 l.kg-1.",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[l] / [kg],2.16,67865,DB00599,Thiopental
,8751034,distribution (t1/2 alpha),"The distribution (t1/2 alpha) and elimination (t1/2 beta) half-lives were 0.590 and 5.89 h, respectively, and the mean residence time (MRT) was 7.44 h.",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),h,0.590,67866,DB00599,Thiopental
,8751034,elimination (t1/2 beta) half-lives,"The distribution (t1/2 alpha) and elimination (t1/2 beta) half-lives were 0.590 and 5.89 h, respectively, and the mean residence time (MRT) was 7.44 h.",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),h,5.89,67867,DB00599,Thiopental
,8751034,mean residence time (MRT),"The distribution (t1/2 alpha) and elimination (t1/2 beta) half-lives were 0.590 and 5.89 h, respectively, and the mean residence time (MRT) was 7.44 h.",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),h,7.44,67868,DB00599,Thiopental
,8751034,clearance,The clearance was 5.41 ml.min-1.kg-1.,Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[ml] / [kg·min],5.41,67869,DB00599,Thiopental
,8751034,steady-state trough plasma concentration (Cmin obs),The steady-state trough plasma concentration (Cmin obs) ranged from 4.8 to 30 mg.l-1 (mean 16.0 mg.l-1 and median 14.3 mg.l-1).,Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[mg] / [l],16.0,67870,DB00599,Thiopental
,8751034,steady-state trough plasma concentration (Cmin obs),The steady-state trough plasma concentration (Cmin obs) ranged from 4.8 to 30 mg.l-1 (mean 16.0 mg.l-1 and median 14.3 mg.l-1).,Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[mg] / [l],14.3,67871,DB00599,Thiopental
,8751034,Peak concentrations (Cmax obs),"Peak concentrations (Cmax obs) ranged from 8.35 to 45 mg.l-1 (25.4 mg.l-1, and median 23.3 mg.l-1).",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[mg] / [l],8.35 to 45,67872,DB00599,Thiopental
,8751034,Peak concentrations (Cmax obs),"Peak concentrations (Cmax obs) ranged from 8.35 to 45 mg.l-1 (25.4 mg.l-1, and median 23.3 mg.l-1).",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[mg] / [l],25.4,67873,DB00599,Thiopental
,8751034,Peak concentrations (Cmax obs),"Peak concentrations (Cmax obs) ranged from 8.35 to 45 mg.l-1 (25.4 mg.l-1, and median 23.3 mg.l-1).",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[mg] / [l],23.3,67874,DB00599,Thiopental
,8751034,V1,"For V1, the mean was 0.333 l.kg-1.",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[l] / [kg],0.333,67875,DB00599,Thiopental
,8751034,Vss,"The mean Vss was 2.68 l.kg-1, with a CVintra of 12.6 to 56% and a CVinter of 13.2%.",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[l] / [kg],2.68,67876,DB00599,Thiopental
,8751034,distribution half-life t1/2 alpha,A shorter distribution half-life t1/2 alpha was noted on multiple dosing; the mean value was 0.122 h.,Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),h,0.122,67877,DB00599,Thiopental
,8751034,t1/2 beta,For t1/2 beta the mean value was 16.3 h.,Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),h,16.3,67878,DB00599,Thiopental
,8751034,MRT,"The mean MRT was 21.9 h, CVintra 9.19 to 48.5%, and the CVinter 35.3%.",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),h,21.9,67879,DB00599,Thiopental
,8751034,clearance,"The mean clearance was 2.16 ml.min-1.kg-1, CVintra 7.28 to 25.5%, and the CVinter 20.4%.",Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751034/),[ml] / [kg·min],2.16,67880,DB00599,Thiopental
,1530165,Cp50(asleep),"The Cp50(asleep) for patients in whom concentrations were maintained within +/- 30% for thiopental alone (n = 17) was 7.32 micrograms/mL (95% confidence interval, 5.53-10.95); for thiopental in the presence of fentanyl (n = 18 with a measured fentanyl concentration of 1.27 +/- 0.5 ng/mL), this was 7.22 micrograms/mL (95% confidence interval, 4.83-10.15).","Fentanyl does not alter the ""sleep"" plasma concentration of thiopental. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530165/),[μg] / [ml],7.32,70137,DB00599,Thiopental
,1530165,Cp50(asleep),"The Cp50(asleep) for patients in whom concentrations were maintained within +/- 30% for thiopental alone (n = 17) was 7.32 micrograms/mL (95% confidence interval, 5.53-10.95); for thiopental in the presence of fentanyl (n = 18 with a measured fentanyl concentration of 1.27 +/- 0.5 ng/mL), this was 7.22 micrograms/mL (95% confidence interval, 4.83-10.15).","Fentanyl does not alter the ""sleep"" plasma concentration of thiopental. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530165/),[μg] / [ml],7.22,70138,DB00599,Thiopental
,16634542,Onset times,"Onset times for patients receiving 0.3 mg x kg(-1), 0.6 mg x kg(-1) or 0.9 mg x kg(-1) were 271.5 s, 140.0s and 125.4s, respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),s,271.5,70647,DB00599,Thiopental
,16634542,Onset times,"Onset times for patients receiving 0.3 mg x kg(-1), 0.6 mg x kg(-1) or 0.9 mg x kg(-1) were 271.5 s, 140.0s and 125.4s, respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),s,140.0,70648,DB00599,Thiopental
,16634542,Onset times,"Onset times for patients receiving 0.3 mg x kg(-1), 0.6 mg x kg(-1) or 0.9 mg x kg(-1) were 271.5 s, 140.0s and 125.4s, respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),s,125.4,70649,DB00599,Thiopental
,16634542,25% recovery of twitch height,"There was a dose-dependent increase in clinical durations until 25% recovery of twitch height (17.4 min in 0.3 mg x kg(-1) group, 37.2 min in 0.6 mg x kg(-1) and 60.4 min in 0.9 mg x kg(-1) group).","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,17.4,70650,DB00599,Thiopental
,16634542,25% recovery of twitch height,"There was a dose-dependent increase in clinical durations until 25% recovery of twitch height (17.4 min in 0.3 mg x kg(-1) group, 37.2 min in 0.6 mg x kg(-1) and 60.4 min in 0.9 mg x kg(-1) group).","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,37.2,70651,DB00599,Thiopental
,16634542,25% recovery of twitch height,"There was a dose-dependent increase in clinical durations until 25% recovery of twitch height (17.4 min in 0.3 mg x kg(-1) group, 37.2 min in 0.6 mg x kg(-1) and 60.4 min in 0.9 mg x kg(-1) group).","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,60.4,70652,DB00599,Thiopental
,16634542,elimination half life,"Pharmacokinetic study revealed that elimination half life, steady state volume of distribution and plasma clearance of Org 9426 were 48-76 min, 146-181 ml x kg(-1), and 3.8-4.5 ml x min(-1) x kg(-1), respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,48-76,70653,DB00599,Thiopental
,16634542,steady state volume of distribution,"Pharmacokinetic study revealed that elimination half life, steady state volume of distribution and plasma clearance of Org 9426 were 48-76 min, 146-181 ml x kg(-1), and 3.8-4.5 ml x min(-1) x kg(-1), respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),[ml] / [kg],146-181,70654,DB00599,Thiopental
,16634542,plasma clearance,"Pharmacokinetic study revealed that elimination half life, steady state volume of distribution and plasma clearance of Org 9426 were 48-76 min, 146-181 ml x kg(-1), and 3.8-4.5 ml x min(-1) x kg(-1), respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),[ml] / [kg·min],3.8-4.5,70655,DB00599,Thiopental
,7081683,V3,Significant increases were found in V3 (means 145.9 and 51.2 litres) and in T 1/2 beta (means 781 and 427 minutes) in the elderly.,"Pharmacokinetics and pharmacodynamics of thiopentone, A comparison between young and elderly patients. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7081683/),l,145.9,71372,DB00599,Thiopental
,7081683,V3,Significant increases were found in V3 (means 145.9 and 51.2 litres) and in T 1/2 beta (means 781 and 427 minutes) in the elderly.,"Pharmacokinetics and pharmacodynamics of thiopentone, A comparison between young and elderly patients. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7081683/),l,51.2,71373,DB00599,Thiopental
,7081683,T 1/2 beta,Significant increases were found in V3 (means 145.9 and 51.2 litres) and in T 1/2 beta (means 781 and 427 minutes) in the elderly.,"Pharmacokinetics and pharmacodynamics of thiopentone, A comparison between young and elderly patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7081683/),min,781,71374,DB00599,Thiopental
,7081683,T 1/2 beta,Significant increases were found in V3 (means 145.9 and 51.2 litres) and in T 1/2 beta (means 781 and 427 minutes) in the elderly.,"Pharmacokinetics and pharmacodynamics of thiopentone, A comparison between young and elderly patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7081683/),min,427,71375,DB00599,Thiopental
,8198908,Recovery,Recovery was slowest with the propofol infusion (mean 39.8 (SD 12.9) min when eyes opened on command).,"Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,39.8,72637,DB00599,Thiopental
,8198908,recovery times,"The recovery times were significantly shorter with the three other techniques (propofol bolus 21.9 (9.9) min, thiopentone 23.4 (11.3) min, halothane 20.1 (8.9) min), and the choice among these three methods had no significant influence on the recovery profile.","Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,21.9,72638,DB00599,Thiopental
,8198908,recovery times,"The recovery times were significantly shorter with the three other techniques (propofol bolus 21.9 (9.9) min, thiopentone 23.4 (11.3) min, halothane 20.1 (8.9) min), and the choice among these three methods had no significant influence on the recovery profile.","Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,23.4,72639,DB00599,Thiopental
,8198908,recovery times,"The recovery times were significantly shorter with the three other techniques (propofol bolus 21.9 (9.9) min, thiopentone 23.4 (11.3) min, halothane 20.1 (8.9) min), and the choice among these three methods had no significant influence on the recovery profile.","Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,20.1,72640,DB00599,Thiopental
,11512369,mean,"Propofol induction produced a smaller mean arterial pressure increase immediately after intubation than did thiopental induction in adult and elderly groups (101.0 +/- 18.5 and 104.0 +/- 21.1 mmHg in the propofol groups vs. 138.3 +/- 17.1 and 138.9 +/- 16.1 mmHg in the thiopental groups at 1 minute after intubation, p < 0.001 and p = 0.001, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),mmhg,101.0,73765,DB00599,Thiopental
,11512369,mean,"Propofol induction produced a smaller mean arterial pressure increase immediately after intubation than did thiopental induction in adult and elderly groups (101.0 +/- 18.5 and 104.0 +/- 21.1 mmHg in the propofol groups vs. 138.3 +/- 17.1 and 138.9 +/- 16.1 mmHg in the thiopental groups at 1 minute after intubation, p < 0.001 and p = 0.001, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),mmhg,104.0,73766,DB00599,Thiopental
,11512369,heart rate,"Differences in heart rate between propofol and thiopental groups were found in young and adult groups (85.1 +/- 9.2 and 81.7 +/- 10.9 in the propofol groups vs. 94.5 +/- 9.9 and 95.0 +/- 14.0 beats per minute in the thiopental groups at 1 minute after intubation, p = 0.041 and p = 0.029, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),[beats] / [min],85.1,73767,DB00599,Thiopental
,11512369,heart rate,"Differences in heart rate between propofol and thiopental groups were found in young and adult groups (85.1 +/- 9.2 and 81.7 +/- 10.9 in the propofol groups vs. 94.5 +/- 9.9 and 95.0 +/- 14.0 beats per minute in the thiopental groups at 1 minute after intubation, p = 0.041 and p = 0.029, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),[beats] / [min],81.7,73768,DB00599,Thiopental
,11512369,heart rate,"Differences in heart rate between propofol and thiopental groups were found in young and adult groups (85.1 +/- 9.2 and 81.7 +/- 10.9 in the propofol groups vs. 94.5 +/- 9.9 and 95.0 +/- 14.0 beats per minute in the thiopental groups at 1 minute after intubation, p = 0.041 and p = 0.029, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),[beats] / [min],94.5,73769,DB00599,Thiopental
,11512369,heart rate,"Differences in heart rate between propofol and thiopental groups were found in young and adult groups (85.1 +/- 9.2 and 81.7 +/- 10.9 in the propofol groups vs. 94.5 +/- 9.9 and 95.0 +/- 14.0 beats per minute in the thiopental groups at 1 minute after intubation, p = 0.041 and p = 0.029, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),[beats] / [min],95.0,73770,DB00599,Thiopental
,747695,alpha,"The distribution of thiopentone to the tissues was very rapid, the alpha and beta distribution half-lives averaging 2.5 min and 46.4 min respectively for the patient group and 2.8 min and 48.7 min for the control group.",Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),min,2.5,74077,DB00599,Thiopental
,747695,alpha,"The distribution of thiopentone to the tissues was very rapid, the alpha and beta distribution half-lives averaging 2.5 min and 46.4 min respectively for the patient group and 2.8 min and 48.7 min for the control group.",Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),min,2.8,74078,DB00599,Thiopental
,747695,beta distribution half-lives,"The distribution of thiopentone to the tissues was very rapid, the alpha and beta distribution half-lives averaging 2.5 min and 46.4 min respectively for the patient group and 2.8 min and 48.7 min for the control group.",Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),min,46.4,74079,DB00599,Thiopental
,747695,beta distribution half-lives,"The distribution of thiopentone to the tissues was very rapid, the alpha and beta distribution half-lives averaging 2.5 min and 46.4 min respectively for the patient group and 2.8 min and 48.7 min for the control group.",Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),min,48.7,74080,DB00599,Thiopental
,747695,elimination half-life,The mean elimination half-life was 5.1 h for the patients and 5.7 h for the volunteers.,Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),h,5.1,74081,DB00599,Thiopental
,747695,elimination half-life,The mean elimination half-life was 5.1 h for the patients and 5.7 h for the volunteers.,Pharmacokinetics of thiopentone: effects of enflurane and nitrous oxide anaesthesia and surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/747695/),h,5.7,74082,DB00599,Thiopental
,9429044,latencies,The postintubation latencies of Nb waves were 48.9 +/- 8.1 msec (mean +/- SD) in smokers and 48.1 +/- 8.5 msec in non-smokers.,Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),ms,48.9,75529,DB00599,Thiopental
,9429044,latencies,The postintubation latencies of Nb waves were 48.9 +/- 8.1 msec (mean +/- SD) in smokers and 48.1 +/- 8.5 msec in non-smokers.,Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),ms,48.1,75530,DB00599,Thiopental
,9429044,Clearance,"Clearance of thiopentone was 2.9 +/- 1.1 ml.min-1.kg-1 in smokers and 3.3 +/- 1.0 ml.min-1.kg-1 in non-smokers and elimination half life of thiopentone was 12.5 +/- 6.3 hr in smokers and 10.7 +/- 3.1 hr in non-smokers, respectively.",Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),[ml] / [kg·min],2.9,75531,DB00599,Thiopental
,9429044,Clearance,"Clearance of thiopentone was 2.9 +/- 1.1 ml.min-1.kg-1 in smokers and 3.3 +/- 1.0 ml.min-1.kg-1 in non-smokers and elimination half life of thiopentone was 12.5 +/- 6.3 hr in smokers and 10.7 +/- 3.1 hr in non-smokers, respectively.",Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),[ml] / [kg·min],3.3,75532,DB00599,Thiopental
,9429044,elimination half life,"Clearance of thiopentone was 2.9 +/- 1.1 ml.min-1.kg-1 in smokers and 3.3 +/- 1.0 ml.min-1.kg-1 in non-smokers and elimination half life of thiopentone was 12.5 +/- 6.3 hr in smokers and 10.7 +/- 3.1 hr in non-smokers, respectively.",Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),h,12.5,75533,DB00599,Thiopental
,9429044,elimination half life,"Clearance of thiopentone was 2.9 +/- 1.1 ml.min-1.kg-1 in smokers and 3.3 +/- 1.0 ml.min-1.kg-1 in non-smokers and elimination half life of thiopentone was 12.5 +/- 6.3 hr in smokers and 10.7 +/- 3.1 hr in non-smokers, respectively.",Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),h,10.7,75534,DB00599,Thiopental
,9429044,s,"Mean postintubation systolic arterial pressures were 192 +/- 35 vs 189 +/- 20 mmHg and mean postintubation heart rates were 103 +/- 12 vs 102 +/- 17 beat per minute (bpm) in smokers and non-smokers, respectively.",Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),mm,192,75535,DB00599,Thiopental
,9429044,s,"Mean postintubation systolic arterial pressures were 192 +/- 35 vs 189 +/- 20 mmHg and mean postintubation heart rates were 103 +/- 12 vs 102 +/- 17 beat per minute (bpm) in smokers and non-smokers, respectively.",Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),mm,189,75536,DB00599,Thiopental
,9429044,heart rates,"Mean postintubation systolic arterial pressures were 192 +/- 35 vs 189 +/- 20 mmHg and mean postintubation heart rates were 103 +/- 12 vs 102 +/- 17 beat per minute (bpm) in smokers and non-smokers, respectively.",Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),[beat·min] / [bpm],103,75537,DB00599,Thiopental
,9429044,heart rates,"Mean postintubation systolic arterial pressures were 192 +/- 35 vs 189 +/- 20 mmHg and mean postintubation heart rates were 103 +/- 12 vs 102 +/- 17 beat per minute (bpm) in smokers and non-smokers, respectively.",Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429044/),[beat·min] / [bpm],102,75538,DB00599,Thiopental
,9246015,CL,Mean CL and Vc mean population estimates were 8.01 L/hr (133 ml/min or 2.02 ml/min/kg) and 145 L (2.19 L/kg).,Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246015/),[l] / [h],8.01,78282,DB00599,Thiopental
,9246015,Vc,Mean CL and Vc mean population estimates were 8.01 L/hr (133 ml/min or 2.02 ml/min/kg) and 145 L (2.19 L/kg).,Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246015/),[ml] / [kg·min],2.02,78283,DB00599,Thiopental
,9246015,Vc,Mean CL and Vc mean population estimates were 8.01 L/hr (133 ml/min or 2.02 ml/min/kg) and 145 L (2.19 L/kg).,Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246015/),l,145,78284,DB00599,Thiopental
,9246015,Vc,Mean CL and Vc mean population estimates were 8.01 L/hr (133 ml/min or 2.02 ml/min/kg) and 145 L (2.19 L/kg).,Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246015/),[l] / [kg],2.19,78285,DB00599,Thiopental
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,2.2,80742,DB00599,Thiopental
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80743,DB00599,Thiopental
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.3,80744,DB00599,Thiopental
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80745,DB00599,Thiopental
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.8,80746,DB00599,Thiopental
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],1440,80747,DB00599,Thiopental
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],499,80748,DB00599,Thiopental
,9349062,clearance,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],425,80749,DB00599,Thiopental
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,34.9,80750,DB00599,Thiopental
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,21.9,80751,DB00599,Thiopental
,8780280,total plasma clearance (CL),"After IV bolus, the total plasma clearance (CL) (295 +/- 132 mL/min) and volume of distribution at steady state (Vss) (139 +/- 38.5 L) of R-thiopental were significantly greater than those of S-thiopental (230 +/- 104 mL/min and 114 +/- 47.5 L, respectively).",Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),[ml] / [min],295,83910,DB00599,Thiopental
,8780280,volume of distribution at steady state (Vss),"After IV bolus, the total plasma clearance (CL) (295 +/- 132 mL/min) and volume of distribution at steady state (Vss) (139 +/- 38.5 L) of R-thiopental were significantly greater than those of S-thiopental (230 +/- 104 mL/min and 114 +/- 47.5 L, respectively).",Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),l,139,83911,DB00599,Thiopental
,8780280,volume of distribution at steady state (Vss),"After IV bolus, the total plasma clearance (CL) (295 +/- 132 mL/min) and volume of distribution at steady state (Vss) (139 +/- 38.5 L) of R-thiopental were significantly greater than those of S-thiopental (230 +/- 104 mL/min and 114 +/- 47.5 L, respectively).",Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),l,114,83912,DB00599,Thiopental
,8780280,fu,The fu of R-thiopental (12.4% +/- 0.6%) was significantly greater than that of S-thiopental (10.0% +/- 1.0%).,Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),%,12.4,83913,DB00599,Thiopental
,8780280,fu,The fu of R-thiopental (12.4% +/- 0.6%) was significantly greater than that of S-thiopental (10.0% +/- 1.0%).,Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),%,10.0,83914,DB00599,Thiopental
,7235274,Percentage bound,"Percentage bound ranged from 96.7 (n equals 4, SD equals 0.8) at 150 micrograms/ml.",Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235274/),,96.7,85090,DB00599,Thiopental
,7235274,initial distribution volume,"Mean pharmacokinetic parameters obtained for thiopental in the surgical patients were as follows: initial distribution volume 13.81 (SD equals 9.4), apparent volume of distribution 233 1 (SD equals 98), volume of distribution at steady state 97.51 (SD equals 40), elimination half-life 11.5 h (SD equals 1.0) and systemic plasma clearance 0.150 l/min (SD equals 0.063).",Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235274/),,13.81,85091,DB00599,Thiopental
,7235274,apparent volume of distribution,"Mean pharmacokinetic parameters obtained for thiopental in the surgical patients were as follows: initial distribution volume 13.81 (SD equals 9.4), apparent volume of distribution 233 1 (SD equals 98), volume of distribution at steady state 97.51 (SD equals 40), elimination half-life 11.5 h (SD equals 1.0) and systemic plasma clearance 0.150 l/min (SD equals 0.063).",Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235274/),,233 1,85092,DB00599,Thiopental
,7235274,volume of distribution at steady state,"Mean pharmacokinetic parameters obtained for thiopental in the surgical patients were as follows: initial distribution volume 13.81 (SD equals 9.4), apparent volume of distribution 233 1 (SD equals 98), volume of distribution at steady state 97.51 (SD equals 40), elimination half-life 11.5 h (SD equals 1.0) and systemic plasma clearance 0.150 l/min (SD equals 0.063).",Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235274/),,97.51,85093,DB00599,Thiopental
,7235274,elimination half-life,"Mean pharmacokinetic parameters obtained for thiopental in the surgical patients were as follows: initial distribution volume 13.81 (SD equals 9.4), apparent volume of distribution 233 1 (SD equals 98), volume of distribution at steady state 97.51 (SD equals 40), elimination half-life 11.5 h (SD equals 1.0) and systemic plasma clearance 0.150 l/min (SD equals 0.063).",Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235274/),h,11.5,85094,DB00599,Thiopental
,7235274,systemic plasma clearance,"Mean pharmacokinetic parameters obtained for thiopental in the surgical patients were as follows: initial distribution volume 13.81 (SD equals 9.4), apparent volume of distribution 233 1 (SD equals 98), volume of distribution at steady state 97.51 (SD equals 40), elimination half-life 11.5 h (SD equals 1.0) and systemic plasma clearance 0.150 l/min (SD equals 0.063).",Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235274/),[l] / [min],0.150,85095,DB00599,Thiopental
,8827581,half-lives,"The half-lives of equilibration between blood and the brain were estimated to be 0.67 (SEM = 0.07), 0.57 (0.03) and 0.74 (0.05) min for the 250-, 500- and 750-mg doses, respectively, showing that the cerebral concentrations of thiopentone rapidly equilibrate with the afferent blood concentration.",In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827581/),min,0.67,86011,DB00599,Thiopental
,8827581,half-lives,"The half-lives of equilibration between blood and the brain were estimated to be 0.67 (SEM = 0.07), 0.57 (0.03) and 0.74 (0.05) min for the 250-, 500- and 750-mg doses, respectively, showing that the cerebral concentrations of thiopentone rapidly equilibrate with the afferent blood concentration.",In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827581/),min,0.57,86012,DB00599,Thiopental
,8827581,half-lives,"The half-lives of equilibration between blood and the brain were estimated to be 0.67 (SEM = 0.07), 0.57 (0.03) and 0.74 (0.05) min for the 250-, 500- and 750-mg doses, respectively, showing that the cerebral concentrations of thiopentone rapidly equilibrate with the afferent blood concentration.",In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827581/),min,0.74,86013,DB00599,Thiopental
,8827581,half-life,"For the 500-mg dose, the changes in cerebral blood flow could be accounted for by an effect compartment with a half-life of 0.82 min for arterial blood, and 0.00 min for sagittal sinus blood, showing the effluent brain concentrations were in equilibrium with this drug effect.",In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827581/),min,0.82,86014,DB00599,Thiopental
,8827581,half-life,"For the 500-mg dose, the changes in cerebral blood flow could be accounted for by an effect compartment with a half-life of 0.82 min for arterial blood, and 0.00 min for sagittal sinus blood, showing the effluent brain concentrations were in equilibrium with this drug effect.",In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827581/),min,0.00,86015,DB00599,Thiopental
,8827581,half-life,"The time course of the depth of anesthesia for the 250-mg dose could be accounted for by an effect compartment with a half-life of 1.33 min for arterial blood, and 0.41 min for sagittal sinus blood.",In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827581/),min,1.33,86016,DB00599,Thiopental
,8827581,half-life,"The time course of the depth of anesthesia for the 250-mg dose could be accounted for by an effect compartment with a half-life of 1.33 min for arterial blood, and 0.41 min for sagittal sinus blood.",In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827581/),min,0.41,86017,DB00599,Thiopental
,3224534,steady-state thiopental concentration,The mean steady-state thiopental concentration was 13.4 +/- 3.7 micrograms/ml (mean +/- SD) and the average time to reach steady state was 7 +/- 5 h.,Pharmacokinetics of thiopental in the asphyxiated neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224534/),[μg] / [ml],13.4,93879,DB00599,Thiopental
,3224534,time to reach steady state,The mean steady-state thiopental concentration was 13.4 +/- 3.7 micrograms/ml (mean +/- SD) and the average time to reach steady state was 7 +/- 5 h.,Pharmacokinetics of thiopental in the asphyxiated neonate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224534/),h,7,93880,DB00599,Thiopental
,3224534,elimination half-life,"Mean elimination half-life, plasma clearance and volume of distribution for thiopental were 39 h (range 26-70), 66 ml/(h x kg) (range 31-172), and 3.6 liters/kg (range 1.1-6.7), respectively.",Pharmacokinetics of thiopental in the asphyxiated neonate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224534/),h,39,93881,DB00599,Thiopental
,3224534,plasma clearance,"Mean elimination half-life, plasma clearance and volume of distribution for thiopental were 39 h (range 26-70), 66 ml/(h x kg) (range 31-172), and 3.6 liters/kg (range 1.1-6.7), respectively.",Pharmacokinetics of thiopental in the asphyxiated neonate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224534/),[ml] / [h·kg],66,93882,DB00599,Thiopental
,3224534,volume of distribution,"Mean elimination half-life, plasma clearance and volume of distribution for thiopental were 39 h (range 26-70), 66 ml/(h x kg) (range 31-172), and 3.6 liters/kg (range 1.1-6.7), respectively.",Pharmacokinetics of thiopental in the asphyxiated neonate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224534/),[l] / [kg],3.6,93883,DB00599,Thiopental
,8541437,EC50,Calculation of the EC50 resulted in a value of 25.5 +/- 2.0 microM.,[Clonidine increases the anesthetic effectiveness of thiopental]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541437/),μM,25.5,94637,DB00599,Thiopental
,8541437,EC50,In presence of clonidine thiopental exhibited a left shift of the concentration-response curve with an EC50 of 12.3 +/- 1.6 microM (Slope: 2.75 +/- 0.3).,[Clonidine increases the anesthetic effectiveness of thiopental]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541437/),μM,12.3,94638,DB00599,Thiopental
,8541437,Slope,In presence of clonidine thiopental exhibited a left shift of the concentration-response curve with an EC50 of 12.3 +/- 1.6 microM (Slope: 2.75 +/- 0.3).,[Clonidine increases the anesthetic effectiveness of thiopental]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541437/),,2.75,94639,DB00599,Thiopental
,3661922,S-Thiop,Before stopping the infusion after 18/17 min (SD 8/5) (male/female) S-Thiop was (mean (SD) range) 16.0/12.4 (4.6/5.7) 5.9-26.8/5.1-26.6 mg/l; after stop of the infusion 12.8/10.5 (4.5/5.3) 7.6-25.5/4.5-23.4 mg/l. Patients reacted to verbal command after 11.5 (10.3) 11-81 min.,"[Serum thiopental values, spontaneous frontal muscle electromyography activity and compressed EEG amplitudes and frequency values in thiopental infusion anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3661922/),[mg] / [l],16,96222,DB00599,Thiopental
,3661922,S-Thiop,Before stopping the infusion after 18/17 min (SD 8/5) (male/female) S-Thiop was (mean (SD) range) 16.0/12.4 (4.6/5.7) 5.9-26.8/5.1-26.6 mg/l; after stop of the infusion 12.8/10.5 (4.5/5.3) 7.6-25.5/4.5-23.4 mg/l. Patients reacted to verbal command after 11.5 (10.3) 11-81 min.,"[Serum thiopental values, spontaneous frontal muscle electromyography activity and compressed EEG amplitudes and frequency values in thiopental infusion anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3661922/),[mg] / [l],12,96223,DB00599,Thiopental
exceeded,2768407,extraction recovery,Thiopental extraction recovery from fat exceeded 90%.,High-performance liquid chromatographic method for determining thiopental concentrations in twelve rat tissues: application to physiologic modeling of disposition of barbiturate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2768407/),%,90,96669,DB00599,Thiopental
greater,2768407,sensitivity,Assay sensitivity was greater than 1 microgram/ml for tissue and plasma samples as small as 50 microliters.,High-performance liquid chromatographic method for determining thiopental concentrations in twelve rat tissues: application to physiologic modeling of disposition of barbiturate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2768407/),[μg] / [ml],1,96670,DB00599,Thiopental
,8258770,effective thiopental concentrations,Estimates of the mean effective thiopental concentrations affecting 50% of the population (EC50S) for the clinical and EEG endpoints were 11.3 and 33.9 micrograms.,A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258770/),μg,11.3,102627,DB00599,Thiopental
,8258770,effective thiopental concentrations,Estimates of the mean effective thiopental concentrations affecting 50% of the population (EC50S) for the clinical and EEG endpoints were 11.3 and 33.9 micrograms.,A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258770/),μg,33.9,102628,DB00599,Thiopental
,8258770,half-time,The half-time for equilibration between arterial thiopental and the effect compartment was 2.6 min.,A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258770/),min,2.6,102629,DB00599,Thiopental
,8258770,ED50,"Simulation of bolus doses of thiopental with the new model provided ED50s for the clinical and EEG endpoints of 265 mg and 796 mg, respectively; the dose predicted to produce loss of voluntary motor power in 90% of an adult male population was 403 mg.",A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258770/),mg,265,102630,DB00599,Thiopental
,8258770,ED50,"Simulation of bolus doses of thiopental with the new model provided ED50s for the clinical and EEG endpoints of 265 mg and 796 mg, respectively; the dose predicted to produce loss of voluntary motor power in 90% of an adult male population was 403 mg.",A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258770/),mg,79,102631,DB00599,Thiopental
,4043199,recovery time,The mean recovery time was 111 min.,Evaluation of infusion regimens for thiopentone as a primary anaesthetic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043199/),min,111,106071,DB00599,Thiopental
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],6.7,107246,DB00599,Thiopental
,7574009,plasma clearance,"Pharmacokinetic analysis revealed that plasma clearance in the elderly group was significantly decreased compared to that in the younger group (6.7 +/- 2.2 vs 9.5 +/- 2.7 mL.kg-1.min-1, P < 0.05).",Aging alters the pharmacokinetics of pyridostigmine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574009/),[ml] / [kg·min],9.5,107247,DB00599,Thiopental
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.001,107259,DB00599,Thiopental
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.619,107260,DB00599,Thiopental
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.184,107261,DB00599,Thiopental
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.118,107262,DB00599,Thiopental
,2242706,terminal half-life,"The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 l/h/kg, and the steady-state volume of distribution 3.6 l/h/kg.",Thiopental efficacy in phenobarbital-resistant neonatal seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2242706/),h,9,107849,DB00599,Thiopental
,2242706,total plasma clearance,"The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 l/h/kg, and the steady-state volume of distribution 3.6 l/h/kg.",Thiopental efficacy in phenobarbital-resistant neonatal seizures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2242706/),[l] / [h·kg],0.20,107850,DB00599,Thiopental
,2242706,steady-state volume of distribution,"The terminal half-life of thiopental averaged 9 h, the total plasma clearance 0.20 l/h/kg, and the steady-state volume of distribution 3.6 l/h/kg.",Thiopental efficacy in phenobarbital-resistant neonatal seizures. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2242706/),[l] / [h·kg],3.6,107851,DB00599,Thiopental
,2031815,volume of distribution,Mean (SEM) volume of distribution was slightly greater with previous suxamethonium (143 (13) ml kg-1) than without (109 (5) ml kg-1) (P less than 0.04).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ml] / [kg],143,109862,DB00599,Thiopental
,2031815,volume of distribution,Mean (SEM) volume of distribution was slightly greater with previous suxamethonium (143 (13) ml kg-1) than without (109 (5) ml kg-1) (P less than 0.04).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ml] / [kg],109,109863,DB00599,Thiopental
,2031815,elimination half-life,"Mean elimination half-life was unaffected (20.3 (0.8) min and 20.4 (1.6) min, respectively).",Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),min,20.3,109864,DB00599,Thiopental
,2031815,elimination half-life,"Mean elimination half-life was unaffected (20.3 (0.8) min and 20.4 (1.6) min, respectively).",Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),min,20.4,109865,DB00599,Thiopental
,2031815,concentration at 50% block (Cpss50),Atracurium concentration at 50% block (Cpss50) was 305 (30) ng ml-1 with and 454 (25) ng ml-1 without previous suxamethonium (P less than 0.01).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ng] / [ml],305,109866,DB00599,Thiopental
,2031815,concentration at 50% block (Cpss50),Atracurium concentration at 50% block (Cpss50) was 305 (30) ng ml-1 with and 454 (25) ng ml-1 without previous suxamethonium (P less than 0.01).,Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2031815/),[ng] / [ml],454,109867,DB00599,Thiopental
,1348166,Times to 50% recovery of twitch,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,75,111543,DB00599,Thiopental
,1348166,Times to 50% recovery of twitch,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,46,111544,DB00599,Thiopental
,1348166,5%-25% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,14.9,111545,DB00599,Thiopental
,1348166,5%-25% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,10.0,111546,DB00599,Thiopental
,1348166,25%-75% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,38.4,111547,DB00599,Thiopental
,1348166,25%-75% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,16.7,111548,DB00599,Thiopental
,1348166,total volume of distribution,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[ml] / [kg],791,111549,DB00599,Thiopental
,1348166,total volume of distribution,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[ml] / [kg],919,111550,DB00599,Thiopental
,1348166,plasma clearance,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[kg·ml] / [ibw·min],4.65,111551,DB00599,Thiopental
,1348166,plasma clearance,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[kg·ml] / [ibw·min],5.02,111552,DB00599,Thiopental
,1348166,elimination half-life,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,119,111553,DB00599,Thiopental
,1348166,elimination half-life,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,133,111554,DB00599,Thiopental
,8280548,requirement,Mean intraoperative alfentanil requirement was greater in patients with Crohn's disease (2.48 micrograms kg-1 min-1) than in control patients (1.35 micrograms kg-1 min-1) (P < 0.01).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[μg] / [kg·min],2.48,112887,DB00599,Thiopental
,8280548,requirement,Mean intraoperative alfentanil requirement was greater in patients with Crohn's disease (2.48 micrograms kg-1 min-1) than in control patients (1.35 micrograms kg-1 min-1) (P < 0.01).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[μg] / [kg·min],1.35,112888,DB00599,Thiopental
,8280548,elimination half-life,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),min,80,112889,DB00599,Thiopental
,8280548,total plasma clearance,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ml] / [kg·min],5.7,112890,DB00599,Thiopental
,8280548,total plasma clearance,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ml] / [kg·min],6.4,112891,DB00599,Thiopental
,8280548,steady state distribution volume,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ml] / [kg·min],6.4,112892,DB00599,Thiopental
,8280548,steady state distribution volume,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[l] / [kg],0.70,112893,DB00599,Thiopental
,8280548,steady state distribution volume,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[l] / [kg],0.68,112894,DB00599,Thiopental
,8280548,plasma concentration,Mean plasma concentration at which the probability of no response was 50% for the intra-abdominal period of surgery was greater in the Crohn group (359 ng ml-1) than in the control group (199 ng ml-1) (P < 0.02).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ng] / [ml],359,112895,DB00599,Thiopental
,8280548,plasma concentration,Mean plasma concentration at which the probability of no response was 50% for the intra-abdominal period of surgery was greater in the Crohn group (359 ng ml-1) than in the control group (199 ng ml-1) (P < 0.02).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ng] / [ml],199,112896,DB00599,Thiopental
,2223366,extraction ratios,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,0.98,114624,DB00599,Thiopental
,2223366,extraction ratios,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,0.20,114625,DB00599,Thiopental
,2223366,extraction ratios,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,0.44,114626,DB00599,Thiopental
,2223366,net fluxes,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[%·dose] / [min],47,114627,DB00599,Thiopental
,2223366,net fluxes,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[%·dose] / [min],5,114628,DB00599,Thiopental
,2223366,net fluxes,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[%·dose] / [min],20,114629,DB00599,Thiopental
,2223366,clearances,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[l] / [min],1.44,114630,DB00599,Thiopental
,2223366,clearances,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[l] / [min],0.17,114631,DB00599,Thiopental
,2223366,clearances,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[l] / [min],0.80,114632,DB00599,Thiopental
,2223366,renal extraction ratio,"During propofol anaesthesia, arterial blood concentrations of pethidine approximately doubled (P less than 0.05), mean pethidine hepatic extraction ratio was unchanged, flux was increased to 145 (20)% and clearance decreased to 79 (10)% (P less than 0.05) of baseline values; mean pethidine renal extraction ratio, flux and clearance were 73 (34), 112 (43) and 69 (31)% of baseline values; mean hindquarter pethidine extraction ratio decreased to 65 (25)% (P less than 0.05) of baseline values.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,73,114633,DB00599,Thiopental
,12130720,total volume of distribution,"The total volume of distribution of the highly lipophilic drug thiopental was more than 60% larger than that of antipyrine, 53 versus 33 liters, respectively.",The concordance of early antipyrine and thiopental distribution kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130720/),l,53,119036,DB00599,Thiopental
,12130720,total volume of distribution,"The total volume of distribution of the highly lipophilic drug thiopental was more than 60% larger than that of antipyrine, 53 versus 33 liters, respectively.",The concordance of early antipyrine and thiopental distribution kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130720/),l,33,119037,DB00599,Thiopental
,7669465,T1/T0,"Mivacurium chloride was infused at a rate of 15 micrograms kg-1 min-1 for 10 min, 7.5 micrograms kg-1 min-1 for a further 10 min, and then at a rate adjusted to maintain T1/T0 at 5%.","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),%,5,119905,DB00599,Thiopental
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],2.4,119906,DB00599,Thiopental
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],2.1,119907,DB00599,Thiopental
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],3.8,119908,DB00599,Thiopental
,1590573,FiO2,"Anaesthesia was induced with a bolus dose of thiopental 4 mg/kg body wt, fentanyl 7 micrograms/kg and pancuronium 0.1 mg/kg and maintained with a continuous infusion of fentanyl 20 micrograms/min and mechanical ventilation with O2/N2O at an FiO2 of 0.5.",[Hepatic elimination of thiopental in heart surgery patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),,0.,121198,DB00599,Thiopental
,1590573,Cardiac output,"Cardiac output (HZV) also decreased from 6.17 l/min to 4.76 l/min after induction, but remained unchanged at sternotomy (Table 2).",[Hepatic elimination of thiopental in heart surgery patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],6.17,121199,DB00599,Thiopental
,1590573,Cardiac output,"Cardiac output (HZV) also decreased from 6.17 l/min to 4.76 l/min after induction, but remained unchanged at sternotomy (Table 2).",[Hepatic elimination of thiopental in heart surgery patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],4.76,121200,DB00599,Thiopental
,1590573,Hepatic clearance,Hepatic clearance of thiopental as the product of hepatic extraction of thiopental (with a median value of 0.29) and hepatic plasma flow was 0.21 l/min.,[Hepatic elimination of thiopental in heart surgery patients]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),,0.29,121201,DB00599,Thiopental
,1590573,hepatic plasma flow,Hepatic clearance of thiopental as the product of hepatic extraction of thiopental (with a median value of 0.29) and hepatic plasma flow was 0.21 l/min.,[Hepatic elimination of thiopental in heart surgery patients]. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],0.21,121202,DB00599,Thiopental
,1590573,hepatic extraction,Thiopental is subject to a relatively low hepatic extraction of 0.29.,[Hepatic elimination of thiopental in heart surgery patients]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),,0.29,121203,DB00599,Thiopental
,1590573,hepatic clearance,"The hepatic clearance of thiopental found in this study, with an absolute value of 0.21 l/min, is absolutely comparable with the data for total-body clearance reported in the literature.",[Hepatic elimination of thiopental in heart surgery patients]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],0.21,121204,DB00599,Thiopental
,9434278,initial,The mean initial and final clearance rates were 1.22 +/- 0.82 mL/min/kg and 10.5 +/- 23 mL/min/kg.,Time-dependent pharmacokinetics of high dose thiopental infusion in intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9434278/),[ml] / [kg·min],1.22,121481,DB00599,Thiopental
,9434278,final clearance rates,The mean initial and final clearance rates were 1.22 +/- 0.82 mL/min/kg and 10.5 +/- 23 mL/min/kg.,Time-dependent pharmacokinetics of high dose thiopental infusion in intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9434278/),[ml] / [kg·min],10.5,121482,DB00599,Thiopental
,9434278,latency period,The latency period for the first induction averaged 69 +/- 56 h.,Time-dependent pharmacokinetics of high dose thiopental infusion in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9434278/),h,69,121483,DB00599,Thiopental
,20488867,terminal half-life,"In newborn infants undergoing surgery, the terminal half-life of thiopentone was 8 h (interquartile range (IQR) 2.5-10.8), and clearance 0.092 l/min per kg/postnatal age in days (IQR 0.02-0.1).",Placental transfer and pharmacokinetics of thiopentone in newborn infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20488867/),h,8,121990,DB00599,Thiopental
,20488867,clearance,"In newborn infants undergoing surgery, the terminal half-life of thiopentone was 8 h (interquartile range (IQR) 2.5-10.8), and clearance 0.092 l/min per kg/postnatal age in days (IQR 0.02-0.1).",Placental transfer and pharmacokinetics of thiopentone in newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20488867/),[l] / [age·kg·min·postnatal],0.092,121991,DB00599,Thiopental
,7324827,terminal half-life,"The terminal half-life was relatively short, between 91 and 595 min.",Pharmacokinetics of thiopental in caesarian section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324827/),min,91 and 595,123805,DB00599,Thiopental
,7324827,terminal half-lives,The terminal half-lives in the babies ranged from 616 to 2560 min.,Pharmacokinetics of thiopental in caesarian section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324827/),min,616 to 2560,123806,DB00599,Thiopental
,14564614,Plasma clearance,"The respective in vivo and in vitro pharmacokinetic parameters (SCh 1 mg.kg(-1) vs SCh 2 mg.kg(-1)) were as follows: Plasma clearance was 4.17 +/- 2.37 and 1.85 +/- 0.28 l.min(-1), P < 0.05, vs 2.91 +/- 2.01 and 1.27 +/- 0.43 l.min(-1), P < 0.05.",Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564614/),[l] / [min],4.17,124950,DB00599,Thiopental
,14564614,Plasma clearance,"The respective in vivo and in vitro pharmacokinetic parameters (SCh 1 mg.kg(-1) vs SCh 2 mg.kg(-1)) were as follows: Plasma clearance was 4.17 +/- 2.37 and 1.85 +/- 0.28 l.min(-1), P < 0.05, vs 2.91 +/- 2.01 and 1.27 +/- 0.43 l.min(-1), P < 0.05.",Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564614/),[l] / [min],1.85,124951,DB00599,Thiopental
,14564614,Plasma clearance,"The respective in vivo and in vitro pharmacokinetic parameters (SCh 1 mg.kg(-1) vs SCh 2 mg.kg(-1)) were as follows: Plasma clearance was 4.17 +/- 2.37 and 1.85 +/- 0.28 l.min(-1), P < 0.05, vs 2.91 +/- 2.01 and 1.27 +/- 0.43 l.min(-1), P < 0.05.",Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564614/),[l] / [min],2.91,124952,DB00599,Thiopental
,14564614,Plasma clearance,"The respective in vivo and in vitro pharmacokinetic parameters (SCh 1 mg.kg(-1) vs SCh 2 mg.kg(-1)) were as follows: Plasma clearance was 4.17 +/- 2.37 and 1.85 +/- 0.28 l.min(-1), P < 0.05, vs 2.91 +/- 2.01 and 1.27 +/- 0.43 l.min(-1), P < 0.05.",Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564614/),[l] / [min],1.27,124953,DB00599,Thiopental
,14564614,Elimination half-life,"Elimination half-life was 25.4 +/- 10.6 and 47.4 +/- 5.4 s, P < 0.002 vs 26.3 +/- 10.0 and 75.2 +/- 21.8 s, P < 0.00005.",Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564614/),s,25.4,124954,DB00599,Thiopental
,14564614,Elimination half-life,"Elimination half-life was 25.4 +/- 10.6 and 47.4 +/- 5.4 s, P < 0.002 vs 26.3 +/- 10.0 and 75.2 +/- 21.8 s, P < 0.00005.",Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564614/),s,47.4,124955,DB00599,Thiopental
,14564614,Elimination half-life,"Elimination half-life was 25.4 +/- 10.6 and 47.4 +/- 5.4 s, P < 0.002 vs 26.3 +/- 10.0 and 75.2 +/- 21.8 s, P < 0.00005.",Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564614/),s,26.3,124956,DB00599,Thiopental
,14564614,Elimination half-life,"Elimination half-life was 25.4 +/- 10.6 and 47.4 +/- 5.4 s, P < 0.002 vs 26.3 +/- 10.0 and 75.2 +/- 21.8 s, P < 0.00005.",Comparison between in vivo and in vitro pharmacokinetics of succinylcholine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564614/),s,75.2,124957,DB00599,Thiopental
,23719968,total clearance (CL),"The mean values (% relative standard error) for total clearance (CL) and for central volume of distribution (Vd) in patients with and without concomitant esomeprazole were 5.3 L/h (9.2 %) and 256.1 (6.4 %) and 153.2 l (19.2 %), respectively.",Interaction of thiopental with esomeprazole in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719968/),[l] / [h],5.3,129978,DB00599,Thiopental
,23719968,central volume of distribution (Vd),"The mean values (% relative standard error) for total clearance (CL) and for central volume of distribution (Vd) in patients with and without concomitant esomeprazole were 5.3 L/h (9.2 %) and 256.1 (6.4 %) and 153.2 l (19.2 %), respectively.",Interaction of thiopental with esomeprazole in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719968/),l,153.2,129979,DB00599,Thiopental
,7488483,T1/2 beta,"The typical value of T1/2 beta was 4.2 min longer in renal failure than in the healthy patients (34.2 vs 30.0 min, P < 0.005).",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),min,34.2,131865,DB00599,Thiopental
,7488483,T1/2 beta,"The typical value of T1/2 beta was 4.2 min longer in renal failure than in the healthy patients (34.2 vs 30.0 min, P < 0.005).",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),min,30.0,131866,DB00599,Thiopental
,7488483,clearance,"In the healthy patients, clearance of 51W89 was greater in males, but it decreased with increasing age by approximately 1.5 ml min-1 yr-1.",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),[ml] / [min·yr],1.5,131867,DB00599,Thiopental
,9620528,end,General anesthesia was induced with thiopental 4-6 mg/kg and fentanyl 2-4 microg/kg and was maintained with 60% nitrous oxide in oxygen and an end-tidal concentration of 1.5%-2% enflurane.,The pharmacokinetics of vecuronium in male and female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),,1,134931,DB00599,Thiopental
,9620528,volume of the central compartment,"The volume of the central compartment and the volume of distribution at steady state were 39.6 +/- 8.6 and 164.8 +/- 29.3 mL/kg, respectively, in women.",The pharmacokinetics of vecuronium in male and female patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),[ml] / [kg],39.6,134932,DB00599,Thiopental
,9620528,volume of distribution at steady state,"The volume of the central compartment and the volume of distribution at steady state were 39.6 +/- 8.6 and 164.8 +/- 29.3 mL/kg, respectively, in women.",The pharmacokinetics of vecuronium in male and female patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),[ml] / [kg],164.8,134933,DB00599,Thiopental
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,1.4,135041,DB00599,Thiopental
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,1.3,135042,DB00599,Thiopental
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,16,135043,DB00599,Thiopental
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,11,135044,DB00599,Thiopental
,7853456,volume of distribution,"The volume of distribution for the drug was large, especially in the ponies which received isoflurane (1127 +/- 86 ml/kg), compared to the horses which received halothane (742 +/- 89 ml/kg).",Pharmacokinetics of thiopentone in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg],1127,135045,DB00599,Thiopental
,7853456,volume of distribution,"The volume of distribution for the drug was large, especially in the ponies which received isoflurane (1127 +/- 86 ml/kg), compared to the horses which received halothane (742 +/- 89 ml/kg).",Pharmacokinetics of thiopentone in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg],742,135046,DB00599,Thiopental
,7853456,elimination half-life,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,147,135047,DB00599,Thiopental
,7853456,elimination half-life,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,222,135048,DB00599,Thiopental
,7853456,clearance,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg·min],3.5,135049,DB00599,Thiopental
,7853456,clearance,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg·min],3.6,135050,DB00599,Thiopental
,1920600,time to reach early burst suppression,The time to reach early burst suppression was longer in the dog (3.9 +/- 0.5 min) compared with the sheep (3.0 +/- 0.6 min) and the rabbit (2.5 +/- 0.5 min).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),min,3.9,136463,DB00599,Thiopental
,1920600,time to reach early burst suppression,The time to reach early burst suppression was longer in the dog (3.9 +/- 0.5 min) compared with the sheep (3.0 +/- 0.6 min) and the rabbit (2.5 +/- 0.5 min).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),min,3.0,136464,DB00599,Thiopental
,1920600,time to reach early burst suppression,The time to reach early burst suppression was longer in the dog (3.9 +/- 0.5 min) compared with the sheep (3.0 +/- 0.6 min) and the rabbit (2.5 +/- 0.5 min).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),min,2.5,136465,DB00599,Thiopental
,1920600,initial volume of distribution,"The initial volume of distribution was similar in all three species (rabbit, 38.6 +/- 10.0 mg/kg; sheep, 44.5 +/- 9.1 ml/kg; dog, 38.1 +/- 18.4 ml/kg).","A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),[mg] / [kg],38.6,136466,DB00599,Thiopental
,1920600,initial volume of distribution,"The initial volume of distribution was similar in all three species (rabbit, 38.6 +/- 10.0 mg/kg; sheep, 44.5 +/- 9.1 ml/kg; dog, 38.1 +/- 18.4 ml/kg).","A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),[ml] / [kg],44.5,136467,DB00599,Thiopental
,1920600,initial volume of distribution,"The initial volume of distribution was similar in all three species (rabbit, 38.6 +/- 10.0 mg/kg; sheep, 44.5 +/- 9.1 ml/kg; dog, 38.1 +/- 18.4 ml/kg).","A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),[ml] / [kg],38.1,136468,DB00599,Thiopental
,1920600,maximum arterial plasma thiopental concentration,The maximum arterial plasma thiopental concentration achieved at EEG burst suppression was higher in the sheep (221.8 +/- 27.9 micrograms/ml) than the dog (164.7 +/- 29.9 micrograms/ml) or the rabbit (112.3 +/- 15.1 micrograms/ml).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),[μg] / [ml],221.8,136469,DB00599,Thiopental
,1920600,maximum arterial plasma thiopental concentration,The maximum arterial plasma thiopental concentration achieved at EEG burst suppression was higher in the sheep (221.8 +/- 27.9 micrograms/ml) than the dog (164.7 +/- 29.9 micrograms/ml) or the rabbit (112.3 +/- 15.1 micrograms/ml).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),[μg] / [ml],164.7,136470,DB00599,Thiopental
,1920600,maximum arterial plasma thiopental concentration,The maximum arterial plasma thiopental concentration achieved at EEG burst suppression was higher in the sheep (221.8 +/- 27.9 micrograms/ml) than the dog (164.7 +/- 29.9 micrograms/ml) or the rabbit (112.3 +/- 15.1 micrograms/ml).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),[μg] / [ml],112.3,136471,DB00599,Thiopental
,1920600,distribution clearance,Thiopental distribution clearance was slower in the sheep (43.6 +/- 15.1 ml/min/kg) compared with the rabbit (110.5 +/- 18.7 ml/min kg) and the dog (97.2 +/- 47.2 ml/min kg).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),[ml] / [kg·min],43.6,136472,DB00599,Thiopental
,1920600,distribution clearance,Thiopental distribution clearance was slower in the sheep (43.6 +/- 15.1 ml/min/kg) compared with the rabbit (110.5 +/- 18.7 ml/min kg) and the dog (97.2 +/- 47.2 ml/min kg).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),[ml] / [kg·min],110.5,136473,DB00599,Thiopental
,1920600,distribution clearance,Thiopental distribution clearance was slower in the sheep (43.6 +/- 15.1 ml/min/kg) compared with the rabbit (110.5 +/- 18.7 ml/min kg) and the dog (97.2 +/- 47.2 ml/min kg).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),[ml] / [kg·min],97.2,136474,DB00599,Thiopental
,1920600,Elimination half-life,Elimination half-life was extended in the sheep (251.9 +/- 107.8 min) and dog (182.4 +/- 57.9 min) relative to the rabbit (43.1 +/- 3.4 min).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),min,251.9,136475,DB00599,Thiopental
,1920600,Elimination half-life,Elimination half-life was extended in the sheep (251.9 +/- 107.8 min) and dog (182.4 +/- 57.9 min) relative to the rabbit (43.1 +/- 3.4 min).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),min,182.4,136476,DB00599,Thiopental
,1920600,Elimination half-life,Elimination half-life was extended in the sheep (251.9 +/- 107.8 min) and dog (182.4 +/- 57.9 min) relative to the rabbit (43.1 +/- 3.4 min).,"A comparative study of the pharmacokinetics of thiopental in the rabbit, sheep and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920600/),min,43.1,136477,DB00599,Thiopental
,2897149,Vc,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],82,139625,DB00599,Thiopental
,2897149,VDSS,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],277,139626,DB00599,Thiopental
,2897149,clearance,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg·min],2.01,139627,DB00599,Thiopental
,2897149,t1/2 beta,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),min,117,139628,DB00599,Thiopental
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,5944,139629,DB00599,Thiopental
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,1240,139630,DB00599,Thiopental
,6364679,binding,The average binding of thiopental to serum protein shortly after the induction was 83.9% (78.2-88.1) in the renal patients and 89.0% (85.2-91.6) in the control patients (P less than 0.05).,Pharmacokinetics and pharmacodynamics of thiopental in patients undergoing renal transplantation. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364679/),%,83.9,141828,DB00599,Thiopental
,6364679,binding,The average binding of thiopental to serum protein shortly after the induction was 83.9% (78.2-88.1) in the renal patients and 89.0% (85.2-91.6) in the control patients (P less than 0.05).,Pharmacokinetics and pharmacodynamics of thiopental in patients undergoing renal transplantation. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364679/),%,89.0,141829,DB00599,Thiopental
,1687880,low detection limit,The low detection limit of this method in the patient was 3 ng/mL.,Determination of vecuronium in blood by HPLC with UV and electrochemical detection: a pilot study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687880/),[ng] / [ml],3,142308,DB00599,Thiopental
,19583708,Serum thiopental concentration,"Serum thiopental concentration was 82, 59, 42 and 32 micromol/L after 20 min and 6, 24 and 68 h respectively.",Thiopental pharmacokinetics in newborn infants: a case report of overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19583708/),[μM] / [l],82,142562,DB00599,Thiopental
,19583708,Serum thiopental concentration,"Serum thiopental concentration was 82, 59, 42 and 32 micromol/L after 20 min and 6, 24 and 68 h respectively.",Thiopental pharmacokinetics in newborn infants: a case report of overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19583708/),[μM] / [l],59,142563,DB00599,Thiopental
,19583708,Serum thiopental concentration,"Serum thiopental concentration was 82, 59, 42 and 32 micromol/L after 20 min and 6, 24 and 68 h respectively.",Thiopental pharmacokinetics in newborn infants: a case report of overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19583708/),[μM] / [l],42,142564,DB00599,Thiopental
,19583708,Serum thiopental concentration,"Serum thiopental concentration was 82, 59, 42 and 32 micromol/L after 20 min and 6, 24 and 68 h respectively.",Thiopental pharmacokinetics in newborn infants: a case report of overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19583708/),[μM] / [l],32,142565,DB00599,Thiopental
,3304768,half-life,"Dexamethasone is rapidly eliminated, the short half-life (about 3 hours) indicating that dosage intervals should be kept small.",Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304768/),h,3,143709,DB00599,Thiopental
,3304768,elimination half-life,"Following single doses, pentobarbitone has a relatively long elimination half-life (about 22 hours).",Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304768/),h,22,143710,DB00599,Thiopental
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,3.9,149435,DB00599,Thiopental
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,1.2,149436,DB00599,Thiopental
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,107,149437,DB00599,Thiopental
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,31,149438,DB00599,Thiopental
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],20,149439,DB00599,Thiopental
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],18,149440,DB00599,Thiopental
,6492246,rate of change in volume of distribution at zero time,"The rate of change in volume of distribution at zero time (mean +/- SD, n = 7), which is a parameter that might have been expected to vary significantly, was 97 +/- 106 ml/min X kg for thiopental alone and 77 +/- 60 ml/min X kg following acetylpromazine premedication.",Effect of premedication with acetylpromazine on the disposition kinetics of thiopental. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492246/),[ml] / [kg·min],97,158424,DB00599,Thiopental
,6492246,rate of change in volume of distribution at zero time,"The rate of change in volume of distribution at zero time (mean +/- SD, n = 7), which is a parameter that might have been expected to vary significantly, was 97 +/- 106 ml/min X kg for thiopental alone and 77 +/- 60 ml/min X kg following acetylpromazine premedication.",Effect of premedication with acetylpromazine on the disposition kinetics of thiopental. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492246/),[ml] / [kg·min],77,158425,DB00599,Thiopental
,6492246,Body clearance,Body clearance of thiopental was 1.96 +/- 0.59 ml/min X kg in dogs without premedication and 1.55 +/- 0.49 ml/min X kg following acetylpromazine.,Effect of premedication with acetylpromazine on the disposition kinetics of thiopental. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492246/),[ml] / [kg·min],1.96,158426,DB00599,Thiopental
,6492246,Body clearance,Body clearance of thiopental was 1.96 +/- 0.59 ml/min X kg in dogs without premedication and 1.55 +/- 0.49 ml/min X kg following acetylpromazine.,Effect of premedication with acetylpromazine on the disposition kinetics of thiopental. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492246/),[ml] / [kg·min],1.55,158427,DB00599,Thiopental
,2614680,half-life of distribution phase,"Maternal plasma levels of thiopental fell rapidly after injection, distributing into tissues (half-life of distribution phase averaged 3 min).",Placental transfer and tissue distribution of thiopental in the pregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614680/),min,3,160050,DB00599,Thiopental
,2614680,rate constant,Peak levels were seen within 10 min of injection and declined in all tissues parallel to maternal plasma (rate constant range 0.012-0.017 min-1).,Placental transfer and tissue distribution of thiopental in the pregnant rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614680/),1/[min],0.012-0.017,160051,DB00599,Thiopental
,8634762,flow-rate,The flow-rate was 0.9 ml/min.,Determination of (R)-(+)- and (S)-(-)-isomers of thiopentone in plasma by chiral high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8634762/),[ml] / [min],0.9,161137,DB00599,Thiopental
,9597210,Maximum blood thiopentone concentration,"Maximum blood thiopentone concentration in the precipitate group was lower than in the control group (12.9 +/- 4.5 vs 17.0 +/- 1.6 micrograms.ml, P < 0.05), although the half-life of thiopentone in the precipitate group was longer (32.3 +/- 8.5 vs 21.7 +/- 8.2 min, P < 0.05) and the area under the time concentration curve was similar between the two groups.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),ml·μg,12.9,161296,DB00599,Thiopental
,9597210,Maximum blood thiopentone concentration,"Maximum blood thiopentone concentration in the precipitate group was lower than in the control group (12.9 +/- 4.5 vs 17.0 +/- 1.6 micrograms.ml, P < 0.05), although the half-life of thiopentone in the precipitate group was longer (32.3 +/- 8.5 vs 21.7 +/- 8.2 min, P < 0.05) and the area under the time concentration curve was similar between the two groups.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),ml·μg,17.0,161297,DB00599,Thiopental
,9597210,half-life,"Maximum blood thiopentone concentration in the precipitate group was lower than in the control group (12.9 +/- 4.5 vs 17.0 +/- 1.6 micrograms.ml, P < 0.05), although the half-life of thiopentone in the precipitate group was longer (32.3 +/- 8.5 vs 21.7 +/- 8.2 min, P < 0.05) and the area under the time concentration curve was similar between the two groups.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),min,32.3,161298,DB00599,Thiopental
,9597210,half-life,"Maximum blood thiopentone concentration in the precipitate group was lower than in the control group (12.9 +/- 4.5 vs 17.0 +/- 1.6 micrograms.ml, P < 0.05), although the half-life of thiopentone in the precipitate group was longer (32.3 +/- 8.5 vs 21.7 +/- 8.2 min, P < 0.05) and the area under the time concentration curve was similar between the two groups.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),min,21.7,161299,DB00599,Thiopental
,9597210,PaO2,"The PaO2 was lower in the precipitate group than in controls one minute after injection (431 +/- 27 vs 464 +/- 18 mmHg, P < 0.05) but not subsequently.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),mmhg,431,161300,DB00599,Thiopental
,9597210,PaO2,"The PaO2 was lower in the precipitate group than in controls one minute after injection (431 +/- 27 vs 464 +/- 18 mmHg, P < 0.05) but not subsequently.",Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597210/),mmhg,464,161301,DB00599,Thiopental
lower,8582467,plasma clearance,"Overall mean plasma clearance was lower than 1 ml.min-1.kg-1 for one subjects, ranged between 1 and 2 ml.",Variability of thiopental clearance in routine critical care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582467/),[ml] / [kg·min],1,161689,DB00599,Thiopental
,8582467,plasma clearance,"Overall mean plasma clearance was lower than 1 ml.min-1.kg-1 for one subjects, ranged between 1 and 2 ml.",Variability of thiopental clearance in routine critical care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582467/),ml,1 and 2,161690,DB00599,Thiopental
,8582467,apparent daily clearance,Extreme values for apparent daily clearance were 0.268 ml.min-1.kg-1 and 5.40 ml.min-1.kg-1.,Variability of thiopental clearance in routine critical care patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582467/),[ml] / [kg·min],0.268,161691,DB00599,Thiopental
,8582467,apparent daily clearance,Extreme values for apparent daily clearance were 0.268 ml.min-1.kg-1 and 5.40 ml.min-1.kg-1.,Variability of thiopental clearance in routine critical care patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582467/),[ml] / [kg·min],5.40,161692,DB00599,Thiopental
,496054,terminal half-lives,"Plasma disappearances of both drugs were triexponential, with mean terminal half-lives of 346 and 217 min for d-tubocurarine and metocurine, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),min,346,165691,DB00599,Thiopental
,496054,terminal half-lives,"Plasma disappearances of both drugs were triexponential, with mean terminal half-lives of 346 and 217 min for d-tubocurarine and metocurine, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),min,217,165692,DB00599,Thiopental
,496054,Renal excretions,Renal excretions 48 hours after injection ranged from 46 to 95 per cent of the dose for d-tubocurarine and from 46 to 58 per cent for metocurine.,Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),%,46 to 95,165693,DB00599,Thiopental
,496054,Renal excretions,Renal excretions 48 hours after injection ranged from 46 to 95 per cent of the dose for d-tubocurarine and from 46 to 58 per cent for metocurine.,Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),%,46 to 58,165694,DB00599,Thiopental
,496054,total-body clearances,"Mean total-body clearances were 56 and 96 ml/min for d-tubocurarine and metocurine, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),[ml] / [min],56,165695,DB00599,Thiopental
,496054,total-body clearances,"Mean total-body clearances were 56 and 96 ml/min for d-tubocurarine and metocurine, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),[ml] / [min],96,165696,DB00599,Thiopental
,496054,Biliary elimination,"Biliary elimination of d-tubocurarine was greater than that of metocurine: within 48 hours 11.8 and 2.1 per cent of the doses were excreted in bile, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),%,11.8,165697,DB00599,Thiopental
,496054,Biliary elimination,"Biliary elimination of d-tubocurarine was greater than that of metocurine: within 48 hours 11.8 and 2.1 per cent of the doses were excreted in bile, respectively.",Comparative pharmacokinetics of d-tubocurarine and metocurine in man. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/496054/),%,2.1,165698,DB00599,Thiopental
,8149943,Vm,Vm was on average 0.93 +/- 0.57 mg.l-1.h-1.,Non linear disposition of thiopentone following long-term infusion. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149943/),[mg] / [h·l],0.93,167877,DB00599,Thiopental
,8149943,plasma clearance,The mean plasma clearance was 2.0 +/- 1.4 ml.min-1.kg-1.,Non linear disposition of thiopentone following long-term infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149943/),[ml] / [kg·min],2.0,167878,DB00599,Thiopental
,8149943,apparent half-life of the terminal phase,The apparent half-life of the terminal phase was 5.5 +/- 3.9 h.,Non linear disposition of thiopentone following long-term infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149943/),h,5.5,167879,DB00599,Thiopental
,6645788,adipose/,"Adipose/plasma and adipose/lung concentration ratios were 2-5 and 0.05, respectively.",Distribution of chlorpromazine and imipramine in adipose and other tissues of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645788/),,2,169917,DB00599,Thiopental
,6645788,adipose/,"Adipose/plasma and adipose/lung concentration ratios were 2-5 and 0.05, respectively.",Distribution of chlorpromazine and imipramine in adipose and other tissues of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645788/),,0.05,169918,DB00599,Thiopental
,3605671,elimination half-life,"The elimination half-life varied from 0.79 to 2.83 hr, which is shorter than in adult patients.",Midazolam as an induction agent in children: a pharmacokinetic and clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605671/),h,0.79 to 2.83,171083,DB00599,Thiopental
,9209610,half-life of elimination,"The mean half-life of elimination was 47 s with a 95% confidence interval of 24 to 70 s; that of effect compartment equilibration, 211 s with a 95% confidence range of 139 to 282 s.",Pharmacokinetics and pharmacodynamics of suxamethonium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209610/),s,47,172779,DB00599,Thiopental
,9209610,half-life of elimination,"The mean half-life of elimination was 47 s with a 95% confidence interval of 24 to 70 s; that of effect compartment equilibration, 211 s with a 95% confidence range of 139 to 282 s.",Pharmacokinetics and pharmacodynamics of suxamethonium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209610/),s,211,172780,DB00599,Thiopental
,6145374,clearance,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),[ml] / [kg·min],6.4,178725,DB00599,Thiopental
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),min,36,178726,DB00599,Thiopental
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),[ml] / [kg·min],3.0,178727,DB00599,Thiopental
,6145374,elimination half-life,"Vecuronium had a more rapid clearance (6.4 +/- 0.4 ml X kg-1 X min-1, mean +/- SE) and a shorter elimination half-life (36 +/- 1.8 min) than pancuronium (3.0 +/- 0.1 ml X kg-1 X min-1 and 72 +/- 6 min, respectively).","Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145374/),min,72,178728,DB00599,Thiopental
,2363548,octanol/water partition coefficient,"This lipophilic (octanol/water partition coefficient: 1000) and weak base (pKa = 4.5) is a potent short-acting hypnotic agent, which can be used for anaesthetic induction or maintenance.",[Pharmacokinetics of etomidate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),,1000,182659,DB00599,Thiopental
,2363548,pKa,"This lipophilic (octanol/water partition coefficient: 1000) and weak base (pKa = 4.5) is a potent short-acting hypnotic agent, which can be used for anaesthetic induction or maintenance.",[Pharmacokinetics of etomidate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),,4.5,182660,DB00599,Thiopental
,2363548,distribution half-lives,"The plasma concentration curve fits an open three compartment pharmacokinetic model, with distribution half-lives of 2.6 and 20 min, and terminal elimination half-life of about 4-5 h.",[Pharmacokinetics of etomidate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),min,2.6,182661,DB00599,Thiopental
,2363548,distribution half-lives,"The plasma concentration curve fits an open three compartment pharmacokinetic model, with distribution half-lives of 2.6 and 20 min, and terminal elimination half-life of about 4-5 h.",[Pharmacokinetics of etomidate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),min,20,182662,DB00599,Thiopental
,2363548,terminal elimination half-life,"The plasma concentration curve fits an open three compartment pharmacokinetic model, with distribution half-lives of 2.6 and 20 min, and terminal elimination half-life of about 4-5 h.",[Pharmacokinetics of etomidate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),h,4-5,182663,DB00599,Thiopental
,2363548,t1/2,Hypnotic plasma concentrations (greater than 0.2 microgram.ml-1) are observed during the intermediate distribution phase (t1/2 approximately 20 min); they reflect the short lasting pharmacodynamic effect.,[Pharmacokinetics of etomidate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),min,20,182664,DB00599,Thiopental
,8659788,cardiac output,"One minute after the larger dose, cardiac output decreased from baseline (123 +/- 14 to 84 +/- ml.min (-1), P< 0.01), flow to muscle and fat decreased, and muscle and fat resistance increased.",Effects of thiopental on regional blood flows in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659788/),,123,185669,DB00599,Thiopental
,8659788,cardiac output,"One minute after the larger dose, cardiac output decreased from baseline (123 +/- 14 to 84 +/- ml.min (-1), P< 0.01), flow to muscle and fat decreased, and muscle and fat resistance increased.",Effects of thiopental on regional blood flows in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659788/),,84,185670,DB00599,Thiopental
,8659788,cardiac output,"At 5 min, compared to baseline, no difference in cardiac output was detected (123 +/- vs. 119 +/- ml.min (-1)), intestinal flows increased and intestinal resistances decreased.",Effects of thiopental on regional blood flows in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659788/),-1·min·ml,123,185671,DB00599,Thiopental
,8659788,cardiac output,"At 5 min, compared to baseline, no difference in cardiac output was detected (123 +/- vs. 119 +/- ml.min (-1)), intestinal flows increased and intestinal resistances decreased.",Effects of thiopental on regional blood flows in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659788/),-1·min·ml,119,185672,DB00599,Thiopental
,3063133,respiratory rate,"Ventilation was performed mechanically during the entire operative period (N2O/O2 - FiO2:0.33, tidal volume 10 ml/kg, respiratory rate: 14/min).",[Response of human growth hormone to anesthesia induction with propofol]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063133/),1/[min],14,187266,DB00599,Thiopental
,3148286,infusion rate,The infusion rate was reduced to 0.5 microgram/kg/min after ten minutes.,A comparison of alfentanil requirements in European and Asian patients during general anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148286/),[μg] / [kg·min],0.5,189989,DB00599,Thiopental
,3161005,half-life,"After both oral and parenteral administration, midazolam has a fast absorption rate and is rapidly excreted, with a half-life of only about 2 hours.","Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161005/),h,2,191122,DB00599,Thiopental
,6632077,apparent volume of distribution,"The drug had an apparent volume of distribution of 1005 +/- 196 ml/kg; body clearance was 3.5 +/- 0.8 ml/min-kg and the half-life, based on the slope of the terminal portion of the curve, was 196 +/- 64 min.",Thiopentone pharmacokinetics and electrocorticogram pattern in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632077/),[ml] / [kg],1005,200329,DB00599,Thiopental
,6632077,body clearance,"The drug had an apparent volume of distribution of 1005 +/- 196 ml/kg; body clearance was 3.5 +/- 0.8 ml/min-kg and the half-life, based on the slope of the terminal portion of the curve, was 196 +/- 64 min.",Thiopentone pharmacokinetics and electrocorticogram pattern in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632077/),[ml] / [min-kg],3.5,200330,DB00599,Thiopental
,6632077,half-life,"The drug had an apparent volume of distribution of 1005 +/- 196 ml/kg; body clearance was 3.5 +/- 0.8 ml/min-kg and the half-life, based on the slope of the terminal portion of the curve, was 196 +/- 64 min.",Thiopentone pharmacokinetics and electrocorticogram pattern in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632077/),min,196,200331,DB00599,Thiopental
,6632077,brain penetration half-time,"From the electrocorticogram pattern, it seems likely that the highest concentrations in brain occurred between 47 and 217 sec after commencing administration and a brain penetration half-time of 26.5 +/- 2.87 sec was calculated.",Thiopentone pharmacokinetics and electrocorticogram pattern in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6632077/),s,26.5,200332,DB00599,Thiopental
,10598612,steady state clearance (Clss),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),[l] / [min],0.108,208009,DB00599,Thiopental
,10598612,steady state clearance (Clss),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),[l] / [min],0.096,208010,DB00599,Thiopental
,10598612,volume of distribution (Vd),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),l,313,208011,DB00599,Thiopental
,10598612,volume of distribution (Vd),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),l,273,208012,DB00599,Thiopental
,10598612,maximal rate of metabolism (Vm),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),[mg] / [h·l],1.01,208013,DB00599,Thiopental
,10598612,maximal rate of metabolism (Vm),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),[mg] / [h·l],0.86,208014,DB00599,Thiopental
,10598612,elimination half-lives,"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),h,14.6,208015,DB00599,Thiopental
,10598612,elimination half-lives,"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),h,14.7,208016,DB00599,Thiopental
,10598612,unbound fractions (f(u)),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),,0.20,208017,DB00599,Thiopental
,10598612,unbound fractions (f(u)),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),,0.18,208018,DB00599,Thiopental
,15717705,k(ip),"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),1/[min],0.374,211082,DB00599,Thiopental
,15717705,k(ei),"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),1/[min],0.151,211083,DB00599,Thiopental
,15717705,EC50,"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),[μg] / [l],98,211084,DB00599,Thiopental
,15717705,gamma,"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),,3.7,211085,DB00599,Thiopental
,3348533,area under the curve of plasma concentration,"Phenobarbital (16 mg/kg of body weight, PO, q 24 h), administered for 14 days, reduced the area under the curve of plasma concentration of thiopental vs time from 10,688 micrograms.",Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348533/),μg,"10,688",212047,DB00599,Thiopental
,3348533,time to recovery from anesthesia,"Furthermore, the time to recovery from anesthesia (ie, return to standing position) decreased from 103 minutes to 35.7 minutes after phenobarbital.",Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348533/),min,103,212048,DB00599,Thiopental
,3348533,time to recovery from anesthesia,"Furthermore, the time to recovery from anesthesia (ie, return to standing position) decreased from 103 minutes to 35.7 minutes after phenobarbital.",Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348533/),min,35.7,212049,DB00599,Thiopental
,8010470,onset of neuromuscular blockade,The onset of neuromuscular blockade was longer (P < 0.01) in patients with cirrhosis (158 +/- 56 s) than in normal patients (108 +/- 33 s).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),s,158,213175,DB00599,Thiopental
,8010470,onset of neuromuscular blockade,The onset of neuromuscular blockade was longer (P < 0.01) in patients with cirrhosis (158 +/- 56 s) than in normal patients (108 +/- 33 s).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),s,108,213176,DB00599,Thiopental
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,77,213177,DB00599,Thiopental
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,88,213178,DB00599,Thiopental
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,57,213179,DB00599,Thiopental
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,64,213180,DB00599,Thiopental
,8010470,central volume of distribution,The central volume of distribution of rocuronium was 104 +/- 21 in cirrhotic patients and 78 +/- 24 ml.kg-1 in normal patients (P < 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),[ml] / [kg],104,213181,DB00599,Thiopental
,8010470,central volume of distribution,The central volume of distribution of rocuronium was 104 +/- 21 in cirrhotic patients and 78 +/- 24 ml.kg-1 in normal patients (P < 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),[ml] / [kg],78,213182,DB00599,Thiopental
,8010470,elimination half-life,The elimination half-life was 87.5 +/- 17.5 min in normal patients and 96.0 +/- 36.8 min in cirrhotic patients (difference not significant).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,87.5,213183,DB00599,Thiopental
,8010470,elimination half-life,The elimination half-life was 87.5 +/- 17.5 min in normal patients and 96.0 +/- 36.8 min in cirrhotic patients (difference not significant).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,96.0,213184,DB00599,Thiopental
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],1.96,213259,DB00599,Thiopental
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],2.58,213260,DB00599,Thiopental
,8250313,Total plasma clearance,"Total plasma clearance did not differ between controls (2.96 +/- 1.05 mL.min-1.kg-1, mean +/- SD) and cirrhotics (2.61 +/- 1.16 mL.min-1.kg-1).",Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg·min],2.96,215622,DB00599,Thiopental
,8250313,Total plasma clearance,"Total plasma clearance did not differ between controls (2.96 +/- 1.05 mL.min-1.kg-1, mean +/- SD) and cirrhotics (2.61 +/- 1.16 mL.min-1.kg-1).",Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg·min],2.61,215623,DB00599,Thiopental
,8250313,Terminal elimination half-life,Terminal elimination half-life was 111 +/- 46 min in controls and 143 +/- 25 min in cirrhotics.,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),min,111,215624,DB00599,Thiopental
,8250313,Terminal elimination half-life,Terminal elimination half-life was 111 +/- 46 min in controls and 143 +/- 25 min in cirrhotics.,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),min,143,215625,DB00599,Thiopental
,8250313,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state did not differ between controls (350 +/- 81 mL/kg) and cirrhotics (452 +/- 222 mL/kg).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg],350,215626,DB00599,Thiopental
,8250313,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state did not differ between controls (350 +/- 81 mL/kg) and cirrhotics (452 +/- 222 mL/kg).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg],452,215627,DB00599,Thiopental
,8250313,onset of neuromuscular blocking effect,The onset of neuromuscular blocking effect was longer in cirrhotics (233 +/- 112 s) (P < 0.05) than in controls (170 +/- 33 s).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),s,233,215628,DB00599,Thiopental
,8250313,onset of neuromuscular blocking effect,The onset of neuromuscular blocking effect was longer in cirrhotics (233 +/- 112 s) (P < 0.05) than in controls (170 +/- 33 s).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),s,170,215629,DB00599,Thiopental
,2875678,clearance rate,"The alfentanil clearance rate was significantly lower in patients with liver dysfunction (2.3 +/- 1.3 vs 4.2 +/- 2.0 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],2.3,215709,DB00599,Thiopental
,2875678,clearance rate,"The alfentanil clearance rate was significantly lower in patients with liver dysfunction (2.3 +/- 1.3 vs 4.2 +/- 2.0 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],4.2,215710,DB00599,Thiopental
,2875678,clearance rates,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],1.5,215711,DB00599,Thiopental
,2875678,clearance rates,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],4.1,215712,DB00599,Thiopental
,2875678,elimination half-life,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),min,406,215713,DB00599,Thiopental
,2875678,elimination half-life,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),min,87,215714,DB00599,Thiopental
exceeding,2875678,ED95,"For maintenance of hemodynamic stability during superficial and intraabdominal operations, alfentanil serum concentration-response curves revealed ED95 values exceeding 300 ng/ml and 400 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ng] / [ml],300,215715,DB00599,Thiopental
,2875678,ED95,"For maintenance of hemodynamic stability during superficial and intraabdominal operations, alfentanil serum concentration-response curves revealed ED95 values exceeding 300 ng/ml and 400 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ng] / [ml],400,215716,DB00599,Thiopental
,17580185,total gas flow,"Anesthesia was maintained with sevoflurane (2%), O(2), and N(2)O at a total gas flow of 6 L . min(-1) using a semiclosed circle system with a sodalime canister.",Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),[l] / [min],6,221315,DB00599,Thiopental
,17580185,duration of surgery,Mean duration of surgery was 9:06 +/- 0:09 hours.,Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),h,9:06,221316,DB00599,Thiopental
,4060147,LC50,The LC50 value and its 95% confidence limits for an 8-hr exposure of CH3Br was 302 ppm (267-340) ppm.,Neurotoxicity and metabolism of methyl bromide in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4060147/),ppm,302,223027,DB00599,Thiopental
,4060147,half-life,"In a time-course study of CH3Br, bromine, and methyl alcohol, CH3Br was rapidly eliminated from rat tissues following the cessation of exposure, with a half-life of about 30 min in the early post-exposure period.",Neurotoxicity and metabolism of methyl bromide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4060147/),min,30,223028,DB00599,Thiopental
,4060147,half-life,"In contrast, the elimination rate of bromine was very slow, with a half-life about 5 days.",Neurotoxicity and metabolism of methyl bromide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4060147/),d,5,223029,DB00599,Thiopental
,8863278,apparent volumes,The myocardial kinetics for four of the five studies were best described by a single flow-limited compartment with apparent volumes of between 42 and 113 mL.,Myocardial pharmacokinetics of thiopental in sheep after short-term administration: relationship to thiopental-induced reductions in myocardial contractility. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863278/),ml,42 and 113,224695,DB00599,Thiopental
,8863278,half-lives,These volumes equated to half-lives of equilibration between blood and myocardium of between 0.49 and 1.00 min when baseline blood flow was taken into account.,Myocardial pharmacokinetics of thiopental in sheep after short-term administration: relationship to thiopental-induced reductions in myocardial contractility. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863278/),min,0.49 and 1.00,224696,DB00599,Thiopental
,8863278,permeability/flow ratio,The remaining study was better described by a model with a slight membrane limitation (permeability/flow ratio of approximately 2).,Myocardial pharmacokinetics of thiopental in sheep after short-term administration: relationship to thiopental-induced reductions in myocardial contractility. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863278/),,2,224697,DB00599,Thiopental
,6498049,plasma clearance,The plasma clearance of thiopentone was significantly increased from 3.7 +/- 0.9 ml min-1 kg-1 in the controls to 5.4 +/- 2.2 ml min-1 kg-1 in the patients with chronic alcoholism.,Thiopentone pharmacokinetics in patients with chronic alcoholism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498049/),[ml] / [kg·min],3.7,225524,DB00599,Thiopental
,6498049,plasma clearance,The plasma clearance of thiopentone was significantly increased from 3.7 +/- 0.9 ml min-1 kg-1 in the controls to 5.4 +/- 2.2 ml min-1 kg-1 in the patients with chronic alcoholism.,Thiopentone pharmacokinetics in patients with chronic alcoholism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498049/),[ml] / [kg·min],5.4,225525,DB00599,Thiopental
,6498049,terminal elimination half-life,The terminal elimination half-life was of 684 +/- 168 min in the alcoholics and did not differ significantly from the value found in the controls (750 +/- 212 min).,Thiopentone pharmacokinetics in patients with chronic alcoholism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498049/),min,684,225526,DB00599,Thiopental
,6498049,terminal elimination half-life,The terminal elimination half-life was of 684 +/- 168 min in the alcoholics and did not differ significantly from the value found in the controls (750 +/- 212 min).,Thiopentone pharmacokinetics in patients with chronic alcoholism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498049/),min,750,225527,DB00599,Thiopental
,2576345,elimination half-life,"Mean elimination half-life was 215.3 +/- 78.4 min, and the apparent final volume of distribution was 0.58 +/- 0.20 l.kg-1.",[Pharmacokinetics of dextromoramide in the surgical patient]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576345/),min,215.3,225764,DB00599,Thiopental
,2576345,apparent final volume of distribution,"Mean elimination half-life was 215.3 +/- 78.4 min, and the apparent final volume of distribution was 0.58 +/- 0.20 l.kg-1.",[Pharmacokinetics of dextromoramide in the surgical patient]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576345/),[l] / [kg],0.58,225765,DB00599,Thiopental
,2576345,systemic clearance,"Hepatic extraction was low, as shown by a mean systemic clearance of 2.0 +/- 0.9 ml.kg-1.min-1.",[Pharmacokinetics of dextromoramide in the surgical patient]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576345/),[ml] / [kg·min],2.0,225766,DB00599,Thiopental
,8610903,infusion rate requirements to achieve 90% muscle relaxation,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),1/[min·μgram-kg],0.42,227640,DB00599,Thiopental
,8610903,infusion rate requirements to achieve 90% muscle relaxation,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),1/[min·μgram-kg],0.40,227641,DB00599,Thiopental
,8610903,CVEC,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],144.4,227642,DB00599,Thiopental
,8610903,CVEC,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],149.7,227643,DB00599,Thiopental
,8610903,CDES,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],57.2,227644,DB00599,Thiopental
,8610903,CDES,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ng] / [ml],65.3,227645,DB00599,Thiopental
,8610903,clearance,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ml] / [kg·min],2.85,227646,DB00599,Thiopental
,8610903,clearance,"There was no difference between SEV and ISO in the following variables: the vecuronium infusion rate requirements to achieve 90% muscle relaxation (0.42 +/- 0.11 [SEV] vs 0.40 +/- 0.10 [ISO] microgram-kg-1.min-1), CVEC (144.4 +/- 38.1 [SEV] vs 149.7 +/- 69.2 [ISO] ng/mL), CDES (57.2 +/- 20.3 [SEV] vs 65.3 +/- 26.1 [ISO], ng/mL), and plasma vecuronium clearance (2.85 +/- 0.86 [SEV] vs 3.19 +/- 1.24 [ISO] mL.kg-1.min-1).",The effect of sevoflurane and isoflurane on the neuromuscular block produced by vecuronium continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610903/),[ml] / [kg·min],3.19,227647,DB00599,Thiopental
,15595577,infusion rate,Nine patients requiring intensive care therapy and artificial ventilation for several days received piritramide with a median infusion rate of 5 mg h(-1) (range 4.8-10 mg h(-1)) for a median period of 69.9 h (range 49-89 h) for analgesia and sedation.,The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),[mg] / [h],5,230807,DB00599,Thiopental
,15595577,volumes of distribution V1,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,47.9,230808,DB00599,Thiopental
,15595577,V2,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,402,230809,DB00599,Thiopental
,15595577,V3,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,332,230810,DB00599,Thiopental
,15595577,clearances Cl1,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),1/[lh],66.5,230811,DB00599,Thiopental
,15595577,Cl2,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),1/[lh],215,230812,DB00599,Thiopental
,15595577,Cl3,"The concentration-time course after the end of the infusion was adequately described with a three-compartment model in eight patients and a two-compartment model in one patient (standard two-stage geometric mean and 16-84% quantile: volumes of distribution V1 = 47.9 (26.8-85.8)L, V2 = 402 (241-672)L, V3 = 332 (124-885)L; clearances Cl1 = 66.5 (53.2-83.0)Lh(-1), Cl2 = 215 (125-369)Lh(-1), Cl3 = 18.4 (9.2-36.8) Lh(-1)).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),1/[lh],18.4,230813,DB00599,Thiopental
,15595577,steady-state volume of distribution,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,782,230814,DB00599,Thiopental
,15595577,steady-state volume of distribution,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,412.5,230815,DB00599,Thiopental
,15595577,terminal elimination half-life,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),h,17.4,230816,DB00599,Thiopental
,15595577,terminal elimination half-life,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),l,412.5,230817,DB00599,Thiopental
,15595577,terminal elimination half-life,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),h,10.4,230818,DB00599,Thiopental
,15595577,half-time,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),min,285,230819,DB00599,Thiopental
,15595577,half-time,"Both the steady-state volume of distribution (782 L) and the terminal elimination half-life (17.4 h) were larger than predicted from single bolus pharmacokinetic studies (412.5 L and 10.4 h, respectively), the context-sensitive half-time after more than 72 h of administration was 32% shorter than predicted (285 vs. 420 min).",The pharmacokinetics of piritramide after prolonged administration to intensive care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15595577/),min,420,230820,DB00599,Thiopental
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,60,233049,DB00599,Thiopental
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,300,233050,DB00599,Thiopental
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,1.5 to 6,233051,DB00599,Thiopental
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,15,233052,DB00599,Thiopental
,6226471,total body clearance,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),[l] / [min],0.4 to over 1.5,233053,DB00599,Thiopental
,2699288,elimination half-life,"Using non-compartmental analysis, the mean (+/- S.E.M.) elimination half-life, mean residence time, plasma clearance and volume of distribution at steady state were 13.9 +/- 9.2 h, 19.9 +/- 13.4 h, 2.3 Lh-1 and 26.8 +/- 7.9 L respectively.",Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2699288/),h,13.9,234021,DB00599,Thiopental
,2699288,mean residence time,"Using non-compartmental analysis, the mean (+/- S.E.M.) elimination half-life, mean residence time, plasma clearance and volume of distribution at steady state were 13.9 +/- 9.2 h, 19.9 +/- 13.4 h, 2.3 Lh-1 and 26.8 +/- 7.9 L respectively.",Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2699288/),h,19.9,234022,DB00599,Thiopental
,2699288,volume of distribution at steady state,"Using non-compartmental analysis, the mean (+/- S.E.M.) elimination half-life, mean residence time, plasma clearance and volume of distribution at steady state were 13.9 +/- 9.2 h, 19.9 +/- 13.4 h, 2.3 Lh-1 and 26.8 +/- 7.9 L respectively.",Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2699288/),l,26.8,234023,DB00599,Thiopental
,2699288,CSF-plasma concentration ratios,"The mean CSF-plasma concentration ratios for ethmozine at 0.5, 1.0, 2.0, 4.0, 8.0 and 12.0 h were 0.17, 0.14, 0.16, 0.16, 0.23 and 0.22 respectively.",Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2699288/),,0.17,234024,DB00599,Thiopental
,2699288,CSF-plasma concentration ratios,"The mean CSF-plasma concentration ratios for ethmozine at 0.5, 1.0, 2.0, 4.0, 8.0 and 12.0 h were 0.17, 0.14, 0.16, 0.16, 0.23 and 0.22 respectively.",Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2699288/),,0.14,234025,DB00599,Thiopental
,2699288,CSF-plasma concentration ratios,"The mean CSF-plasma concentration ratios for ethmozine at 0.5, 1.0, 2.0, 4.0, 8.0 and 12.0 h were 0.17, 0.14, 0.16, 0.16, 0.23 and 0.22 respectively.",Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2699288/),,0.16,234026,DB00599,Thiopental
,2699288,CSF-plasma concentration ratios,"The mean CSF-plasma concentration ratios for ethmozine at 0.5, 1.0, 2.0, 4.0, 8.0 and 12.0 h were 0.17, 0.14, 0.16, 0.16, 0.23 and 0.22 respectively.",Disposition of ethmozine in cerebrospinal fluid and plasma of rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2699288/),,0.,234027,DB00599,Thiopental
,2919760,elimination half-life,The population average of elimination half-life in neonates was 6.3 hours for midazolam and 14.7 hours for thiopental.,A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia: III. Placental transfer and elimination in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919760/),h,6.3,235743,DB00599,Thiopental
,2919760,elimination half-life,The population average of elimination half-life in neonates was 6.3 hours for midazolam and 14.7 hours for thiopental.,A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia: III. Placental transfer and elimination in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919760/),h,14.7,235744,DB00599,Thiopental
,4014770,Steady state concentrations (Css),Steady state concentrations (Css) were 31.8 +/- 10.7 mg/l for an infusion rate of 3.05 +/- 0.37 mg .,Thiopental pharmacokinetics under conditions of long-term infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014770/),[mg] / [l],31.8,236681,DB00599,Thiopental
,4014770,rate,kg-1 . h-1 and 48.9 +/- 14.6 mg/l for a rate of 4.2 +/- 0.3 mg . kg-1 .,Thiopental pharmacokinetics under conditions of long-term infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014770/),[mg] / [kg],4.2,236682,DB00599,Thiopental
below,4014770,Css,First-order kinetics were only obtained with Css below 30 mg/l.,Thiopental pharmacokinetics under conditions of long-term infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014770/),[mg] / [l],30,236683,DB00599,Thiopental
,4014770,maximum rate of elimination (Vm),"The maximum rate of elimination (Vm) was 1.76 +/- 1.15 mg . l-1 . h-1 (n = 11), and the Michaelis constant (Km) was 26.7 +/- 22.9 mg/l (n = 11).",Thiopental pharmacokinetics under conditions of long-term infusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014770/),[mg] / [h·l],1.76,236684,DB00599,Thiopental
,4014770,Michaelis constant (Km),"The maximum rate of elimination (Vm) was 1.76 +/- 1.15 mg . l-1 . h-1 (n = 11), and the Michaelis constant (Km) was 26.7 +/- 22.9 mg/l (n = 11).",Thiopental pharmacokinetics under conditions of long-term infusion. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014770/),[mg] / [l],26.7,236685,DB00599,Thiopental
,4014770,Hepatic enzyme saturation,Hepatic enzyme saturation was between 35 and 85%.,Thiopental pharmacokinetics under conditions of long-term infusion. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014770/),%,35 and 85,236686,DB00599,Thiopental
,4014770,volume of distribution at steady state,The volume of distribution at steady state was 4.35 +/- 1.83 l/kg (n = 11).,Thiopental pharmacokinetics under conditions of long-term infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014770/),[l] / [kg],4.35,236687,DB00599,Thiopental
,4014770,Apparent half-lives of elimination,"Apparent half-lives of elimination were between 18 and 36 h at the end of infusion, and predicted terminal half-lives were 10.15 +/- 5.43 h (n = 11).",Thiopental pharmacokinetics under conditions of long-term infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014770/),h,18 and 36,236688,DB00599,Thiopental
,4014770,terminal half-lives,"Apparent half-lives of elimination were between 18 and 36 h at the end of infusion, and predicted terminal half-lives were 10.15 +/- 5.43 h (n = 11).",Thiopental pharmacokinetics under conditions of long-term infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014770/),h,10.15,236689,DB00599,Thiopental
,10551581,central volume of distribution,"The central volume of distribution was increased to 131 (104-141) ml/kg in patients with cirrhosis (P < 0.01), compared with 75 (47-146) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],131,237005,DB00599,Thiopental
,10551581,central volume of distribution,"The central volume of distribution was increased to 131 (104-141) ml/kg in patients with cirrhosis (P < 0.01), compared with 75 (47-146) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],75,237006,DB00599,Thiopental
,10551581,total apparent volume of distribution,"The total apparent volume of distribution was also increased (P < 0.05) to 331 (284-488) ml/kg in patients with cirrhosis, compared with 221 (124-285) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],331,237007,DB00599,Thiopental
,10551581,total apparent volume of distribution,"The total apparent volume of distribution was also increased (P < 0.05) to 331 (284-488) ml/kg in patients with cirrhosis, compared with 221 (124-285) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],221,237008,DB00599,Thiopental
,10551581,elimination half-life,The elimination half-life was 88 (77-102) min in controls and 90 (76-117) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,88,237009,DB00599,Thiopental
,10551581,elimination half-life,The elimination half-life was 88 (77-102) min in controls and 90 (76-117) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,90,237010,DB00599,Thiopental
,10551581,Plasma clearance,"Plasma clearance was increased (P < 0.05) to 6.9 (6.1-8.9) ml x min(-1) x kg(-1) in patients with cirrhosis, compared with 5.3 (4.2-8.4) ml x min(-1) x kg(-1) in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg·min],6.9,237011,DB00599,Thiopental
,10551581,Plasma clearance,"Plasma clearance was increased (P < 0.05) to 6.9 (6.1-8.9) ml x min(-1) x kg(-1) in patients with cirrhosis, compared with 5.3 (4.2-8.4) ml x min(-1) x kg(-1) in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg·min],5.3,237012,DB00599,Thiopental
,10551581,Onset time,Onset time was 65 (40-110) s in controls and of 60 (52-240) s in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),s,65,237013,DB00599,Thiopental
,10551581,Onset time,Onset time was 65 (40-110) s in controls and of 60 (52-240) s in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),s,60,237014,DB00599,Thiopental
,10551581,Time to return to 90%,Time to return to 90% of thumb adduction force control value was of 49 (28-80) min in controls and 47 (28-71) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,49,237015,DB00599,Thiopental
,10551581,Time to return to 90%,Time to return to 90% of thumb adduction force control value was of 49 (28-80) min in controls and 47 (28-71) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,47,237016,DB00599,Thiopental
,10389810,steady-state targets,"Rats, either anesthetized with halothane or conscious and restrained, were infused to stepwise steady-state targets of 5, 10, and 20 microg/mL thiopental by computer-controlled infusions.",Enantioselectivity of thiopental distribution into the central neural tissue of rats: an interaction with halothane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389810/),[μg] / [ml],5,239161,DB00599,Thiopental
,10389810,steady-state targets,"Rats, either anesthetized with halothane or conscious and restrained, were infused to stepwise steady-state targets of 5, 10, and 20 microg/mL thiopental by computer-controlled infusions.",Enantioselectivity of thiopental distribution into the central neural tissue of rats: an interaction with halothane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389810/),[μg] / [ml],10,239162,DB00599,Thiopental
,10389810,steady-state targets,"Rats, either anesthetized with halothane or conscious and restrained, were infused to stepwise steady-state targets of 5, 10, and 20 microg/mL thiopental by computer-controlled infusions.",Enantioselectivity of thiopental distribution into the central neural tissue of rats: an interaction with halothane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389810/),[μg] / [ml],20,239163,DB00599,Thiopental
,7235275,initial distribution volume (V1),"Mean values of pharmacokinetic parameters (plus or minus SD) were: initial distribution volume (V1) 17.31 (plus or minus 8.5), apparent volume of distribution (Vdbeta) 564 1 (plus or minus 343), volume of distribution at steady state (Vss) 2881 (plus or minus 180), systemic plasma clearance (Clp) 0.286 l/min (plus or minus 0.156), rate of change of volume of distribution at zero time (RVd0) 1.03 l/min (plus or minus 0.36) and elimination half-life (t1/2) 26.1 h (plus or minus 12.6).",Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235275/),,17.31,242030,DB00599,Thiopental
,7235275,apparent volume of distribution (Vdbeta),"Mean values of pharmacokinetic parameters (plus or minus SD) were: initial distribution volume (V1) 17.31 (plus or minus 8.5), apparent volume of distribution (Vdbeta) 564 1 (plus or minus 343), volume of distribution at steady state (Vss) 2881 (plus or minus 180), systemic plasma clearance (Clp) 0.286 l/min (plus or minus 0.156), rate of change of volume of distribution at zero time (RVd0) 1.03 l/min (plus or minus 0.36) and elimination half-life (t1/2) 26.1 h (plus or minus 12.6).",Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235275/),1,564,242031,DB00599,Thiopental
,7235275,volume of distribution at steady state (Vss),"Mean values of pharmacokinetic parameters (plus or minus SD) were: initial distribution volume (V1) 17.31 (plus or minus 8.5), apparent volume of distribution (Vdbeta) 564 1 (plus or minus 343), volume of distribution at steady state (Vss) 2881 (plus or minus 180), systemic plasma clearance (Clp) 0.286 l/min (plus or minus 0.156), rate of change of volume of distribution at zero time (RVd0) 1.03 l/min (plus or minus 0.36) and elimination half-life (t1/2) 26.1 h (plus or minus 12.6).",Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235275/),,2881,242032,DB00599,Thiopental
,7235275,systemic plasma clearance (Clp),"Mean values of pharmacokinetic parameters (plus or minus SD) were: initial distribution volume (V1) 17.31 (plus or minus 8.5), apparent volume of distribution (Vdbeta) 564 1 (plus or minus 343), volume of distribution at steady state (Vss) 2881 (plus or minus 180), systemic plasma clearance (Clp) 0.286 l/min (plus or minus 0.156), rate of change of volume of distribution at zero time (RVd0) 1.03 l/min (plus or minus 0.36) and elimination half-life (t1/2) 26.1 h (plus or minus 12.6).",Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235275/),[l] / [min],0.286,242033,DB00599,Thiopental
,7235275,elimination half-life (t1/2),"Mean values of pharmacokinetic parameters (plus or minus SD) were: initial distribution volume (V1) 17.31 (plus or minus 8.5), apparent volume of distribution (Vdbeta) 564 1 (plus or minus 343), volume of distribution at steady state (Vss) 2881 (plus or minus 180), systemic plasma clearance (Clp) 0.286 l/min (plus or minus 0.156), rate of change of volume of distribution at zero time (RVd0) 1.03 l/min (plus or minus 0.36) and elimination half-life (t1/2) 26.1 h (plus or minus 12.6).",Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7235275/),h,26.1,242034,DB00599,Thiopental
,8462537,half-lives of elimination,"The half-lives of elimination are respectively 3 min for nicomorphine, 3 and 15 min for 6-nicotinoylmorphine, and 135-190 min for morphine.",Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462537/),min,3,247956,DB00599,Thiopental
,8462537,half-lives of elimination,"The half-lives of elimination are respectively 3 min for nicomorphine, 3 and 15 min for 6-nicotinoylmorphine, and 135-190 min for morphine.",Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462537/),min,15,247957,DB00599,Thiopental
,8462537,half-lives of elimination,"The half-lives of elimination are respectively 3 min for nicomorphine, 3 and 15 min for 6-nicotinoylmorphine, and 135-190 min for morphine.",Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462537/),min,135-190,247958,DB00599,Thiopental
,9234869,Recovery,Recovery from plasma averaged 88%.,High-performance liquid chromatographic assay for thiopental in human plasma. Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234869/),%,88,250568,DB00599,Thiopental
at,9234869,Percent recovery,Percent recovery was at least 93%.,High-performance liquid chromatographic assay for thiopental in human plasma. Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9234869/),%,93,250569,DB00599,Thiopental
,8611958,flow-rate,The mobile phase was 4.5% 2-propanol in 0.1 M phosphate buffer (pH 6.2) with a flow-rate of 0.9 ml/min.,High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),[ml] / [min],0.9,252593,DB00599,Thiopental
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,1.92,252594,DB00599,Thiopental
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,2.92,252595,DB00599,Thiopental
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,5.71,252596,DB00599,Thiopental
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,9.30,252597,DB00599,Thiopental
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,11.98,252598,DB00599,Thiopental
,7893030,plasma clearance,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),[ml] / [min],217,252827,DB00599,Thiopental
,7893030,volume of the central compartment,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,5.96,252828,DB00599,Thiopental
,7893030,volume of the central compartment,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,7.87,252829,DB00599,Thiopental
,7893030,volume of distribution at steady state,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,16.4,252830,DB00599,Thiopental
,7893030,volume of distribution at steady state,"Hepatic impairment did not alter the plasma clearance of rocuronium (217 +/- 21.8 mL/min, mean +/- SE, for both groups), but did increase the volume of the central compartment (5.96 +/- 1.01 L for controls, 7.87 +/- 1.33 L for patients with liver disease) and volume of distribution at steady state (16.4 L for controls, 23.4 L for patients with liver disease).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),l,23.4,252831,DB00599,Thiopental
,7893030,elimination half-life,"In turn, elimination half-life was longer in patients with liver disease (111 min) compared to controls (75.4 min).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),min,111,252832,DB00599,Thiopental
,7893030,elimination half-life,"In turn, elimination half-life was longer in patients with liver disease (111 min) compared to controls (75.4 min).",The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893030/),min,75.4,252833,DB00599,Thiopental
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,53.7,258187,DB00599,Thiopental
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,42.3,258188,DB00599,Thiopental
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,73.9,258189,DB00599,Thiopental
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,52.6,258190,DB00599,Thiopental
,9278198,75% recovery,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258191,DB00599,Thiopental
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258192,DB00599,Thiopental
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,66.8,258193,DB00599,Thiopental
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,114.9,258194,DB00599,Thiopental
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,76.1,258195,DB00599,Thiopental
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],2.66,258196,DB00599,Thiopental
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],3.70,258197,DB00599,Thiopental
,9278198,redistribution (,"The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258198,DB00599,Thiopental
,9278198,"t1/2,lambda1","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258199,DB00599,Thiopental
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,16.8,258200,DB00599,Thiopental
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,143,258201,DB00599,Thiopental
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,92,258202,DB00599,Thiopental
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.25,258203,DB00599,Thiopental
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.16,258204,DB00599,Thiopental
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,20,260546,DB00599,Thiopental
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,39,260547,DB00599,Thiopental
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260548,DB00599,Thiopental
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260549,DB00599,Thiopental
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260550,DB00599,Thiopental
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260551,DB00599,Thiopental
,9029749,elimination half-life,No significant difference was found between the two groups in spite of a 33% decrease of the elimination half-life in children (11.7 +/- 5.7 h) compared with adults (17.5 +/- 9.03 h).,Pharmacokinetics of high-dose thiopental in pediatric patients with increased intracranial pressure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029749/),h,11.7,260852,DB00599,Thiopental
,9029749,elimination half-life,No significant difference was found between the two groups in spite of a 33% decrease of the elimination half-life in children (11.7 +/- 5.7 h) compared with adults (17.5 +/- 9.03 h).,Pharmacokinetics of high-dose thiopental in pediatric patients with increased intracranial pressure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029749/),h,17.5,260853,DB00599,Thiopental
,9029749,total clearance,"The mean values obtained were 2.42 and 2.19 ml/min/kg for total clearance and 2.18 and 2.90 L/kg for Vd in pediatric and adult groups, respectively.",Pharmacokinetics of high-dose thiopental in pediatric patients with increased intracranial pressure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029749/),[ml] / [kg·min],2.42,260854,DB00599,Thiopental
,9029749,total clearance,"The mean values obtained were 2.42 and 2.19 ml/min/kg for total clearance and 2.18 and 2.90 L/kg for Vd in pediatric and adult groups, respectively.",Pharmacokinetics of high-dose thiopental in pediatric patients with increased intracranial pressure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029749/),[ml] / [kg·min],2.19,260855,DB00599,Thiopental
,9029749,Vd,"The mean values obtained were 2.42 and 2.19 ml/min/kg for total clearance and 2.18 and 2.90 L/kg for Vd in pediatric and adult groups, respectively.",Pharmacokinetics of high-dose thiopental in pediatric patients with increased intracranial pressure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029749/),[l] / [kg],2.18,260856,DB00599,Thiopental
,9029749,Vd,"The mean values obtained were 2.42 and 2.19 ml/min/kg for total clearance and 2.18 and 2.90 L/kg for Vd in pediatric and adult groups, respectively.",Pharmacokinetics of high-dose thiopental in pediatric patients with increased intracranial pressure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029749/),[l] / [kg],2.90,260857,DB00599,Thiopental
,3608752,elimination half-life,Thiopental elimination half-life was 14.5 h (group A) and 20.9 h (group B).,High-dose thiopental pharmacokinetics in brain-injured children and neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608752/),h,14.5,270550,DB00599,Thiopental
,3608752,elimination half-life,Thiopental elimination half-life was 14.5 h (group A) and 20.9 h (group B).,High-dose thiopental pharmacokinetics in brain-injured children and neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608752/),h,20.9,270551,DB00599,Thiopental
,3608752,clearance,The clearance of thiopental was 0.27 liters X h-1 X kg-1 (group A) and 0.32 liters X h-1 X kg-1 (group B).,High-dose thiopental pharmacokinetics in brain-injured children and neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608752/),[l] / [h·kg],0.27,270552,DB00599,Thiopental
,3608752,clearance,The clearance of thiopental was 0.27 liters X h-1 X kg-1 (group A) and 0.32 liters X h-1 X kg-1 (group B).,High-dose thiopental pharmacokinetics in brain-injured children and neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608752/),[l] / [h·kg],0.32,270553,DB00599,Thiopental
,3608752,volume of distribution at steady-state,The volume of distribution at steady-state was 5.41 liters X kg-1 (group A) and 8.26 liters X kg-1 (group B).,High-dose thiopental pharmacokinetics in brain-injured children and neonates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608752/),[l] / [kg],5.41,270554,DB00599,Thiopental
,3608752,volume of distribution at steady-state,The volume of distribution at steady-state was 5.41 liters X kg-1 (group A) and 8.26 liters X kg-1 (group B).,High-dose thiopental pharmacokinetics in brain-injured children and neonates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608752/),[l] / [kg],8.26,270555,DB00599,Thiopental
,3608752,time for disappearance,The time for disappearance of thiopental from blood is also very long (2 to 5 days).,High-dose thiopental pharmacokinetics in brain-injured children and neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608752/),d,2 to 5,270556,DB00599,Thiopental
,7349330,half-time of the initial phase,"The half-time of the initial phase, which comprises distribution/redistribution, was 14.9 +/- 3.3 mins.",The pharmacokinetics of thiopentone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349330/),min,14.9,272879,DB00599,Thiopental
,7349330,apparent volume of distribution,The apparent volume of distribution was quite high for an organic acid (843 +/- 194 ml/kg).,The pharmacokinetics of thiopentone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349330/),[ml] / [kg],843,272880,DB00599,Thiopental
,7349330,half-life,The half-life was 6.99 +/- 2.18 h and a body clearance value of 1.51 +/- 0.60 ml/kg-min was obtained.,The pharmacokinetics of thiopentone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349330/),h,6.99,272881,DB00599,Thiopental
,7349330,body clearance,The half-life was 6.99 +/- 2.18 h and a body clearance value of 1.51 +/- 0.60 ml/kg-min was obtained.,The pharmacokinetics of thiopentone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349330/),[ml] / [kg-min],1.51,272882,DB00599,Thiopental
